Next Article in Journal
A Multigene Signature for Prognostic Stratification of Nasopharyngeal Carcinoma
Previous Article in Journal
Do All Stage IA Pancreatic Cancer Patients Need Adjuvant Chemotherapy?
Previous Article in Special Issue
Pharmacologic Targeting of miR29b with Bortezomib and Sorafenib to Improve Decitabine Sensitivity in Patients with Acute Myeloid Leukemia: Results from a Phase 1 Dose-Escalation Trial
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 18
Issue 8
10.3390/cancers18081196
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Triptolide: A Narrative Review of Its Traditional Use, Derivatives, Pharmacology, Antitumor Effect, and Clinical Applications

by
Yibo Geng
1,2,
Bettina Kritzer
1 and
Javad Nazarian
1,*
1
DIPG/DMG Center Zurich, Children’s Research Center, University Children’s Hospital Zurich, University of Zurich, August-Forel-Strasse 51, 8008 Zurich, Switzerland
2
Department of Neurosurgry, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongti South Road, Beijing 100020, China
*
Author to whom correspondence should be addressed.
Cancers 2026, 18(8), 1196; https://doi.org/10.3390/cancers18081196
Submission received: 5 March 2026 / Revised: 2 April 2026 / Accepted: 4 April 2026 / Published: 9 April 2026
(This article belongs to the Special Issue Preclinical and Clinical Research on the Efficacy of Anticancer Drugs)
Browse Figures
Versions Notes

Simple Summary

Triptolide, a compound from a traditional medicinal plant, shows strong anticancer effects but with observed toxicities. As such, its clinical utility may be limited. New derivatives are being developed to overcome this problem. This review summarises the natural source of triptolide and its traditional uses. We also highlight drug metabolism and its mechanisms of action in killing tumor cells. We further discuss prodrugs and their efficacy and potential toxicities. We then discuss registered clinical trials of promising derivative called Minnelide. By evaluating both the potential and the risks of its use, this review aims to guide the development of safer, more effective triptolide-based cancer therapies.

Abstract

Triptolide (TPL), a diterpenoid derived from the Chinese medicinal plant Tripterygium wilfordii, exhibits broad-spectrum biological and pharmacological activities, although its clinical translation is limited by systemic toxicity. Recent advances in the development of TPL derivatives have created new therapeutic opportunities. This review summarizes current knowledge of triptolide, with a focus on TPL’s toxicity profile, derivative strategies, and antitumor mechanisms across different tumor types, including glioma, pancreatic tumor, leukemia, lung cancer, gastric cancer and others. We also summarize the plant’s origin and traditional uses, TPL’s pharmacokinetics (PKs), and relevant clinical trials against tumors. The main mechanism of the TPL antitumor effect is to interfere with ATPase of XPB by covalently binding to it, as well as inducing the rapid depletion of RPB1 via hyperphosphorylation and ubiquitination. We also reviewed systemic toxicity including neuro-, cardio-, oto-, nephron-, hepato-, and hemato-toxicity, as well as digestive and reproductive toxicity. Finally, we searched clinical trial databases across three platforms for tumors and concluded that Minnelide has strong clinical potential for solid tumors. By critically evaluating TPL from multiple dimensions, specifically its traditional use, chemical derivatization, pharmacokinetics, antitumor mechanisms, toxicity, and clinical trials, this review aims to inform future strategies that maximize therapeutic efficacy while minimizing adverse effects.

1. Introduction

Tripterygium wilfordii Hook. f. (TwHF), known in Chinese as “Leigongteng”, holds a significant place in traditional Chinese medicine, with documented uses dating back centuries [1]. Despite its historical application in treating conditions including rheumatoid arthritis and skin disorders, the TPL’s apparent toxicity has limited its wider clinical applications. Triptolide (TPL), a key bioactive diterpenoid triepoxide, was isolated from TwHF in the 1970s and was found to have pharmacological potential, particularly as a potent antitumor agent in medulloblastoma, pancreatic cancer, and leukemia in vivo [2,3,4]. The TPL mechanism of action includes indirect degradation of RNA polymerase II and inhibition of the transcription factor XPB [5]. As such, TPL has shown efficacy across a wide spectrum of cancers, including glioma, pancreatic cancer, lung cancer, and leukemia. However, the clinical translation of TPL has been hampered by its poor solubility and systemic toxicity [6]. In recent years, extensive research has focused on overcoming these challenges through the synthesis of novel derivatives and the development of advanced drug-delivery systems [7].
Recently, several reviews have focused on distinct aspects of TPL. Cui et al. reviewed 12 anticancer compounds derived from herbal medicine and summarized the roles of TPL in the tumor immune microenvironment, drug resistance, mechanisms, toxicity and prodrug development across various tumor types [8]. Feng et al. provided a comprehensive overview centered on the anticancer mechanism and derivatives of TPL [9]. AbdulHussein et al. focused on the mechanisms of cell death induced by TPL in various cancers, including apoptosis, autophagy, senescence, pyroptosis and necrosis [10]. In addition, several reviews have concentrated on specific organs or systems, such as gynecological, hematological, breast, liver, lung and pancreatic cancer [7,11,12,13,14]. Although these reviews synthesized original research and provided valuable insight into their respective topics, most lack illustrative figures or tables, which may hinder readers’ understanding. Thus, this review aims to provide a comprehensive, reader-friendly and up-to-date synthesis of the traditional uses, chemical derivatization, pharmacology, antitumor mechanisms, and the current status of clinical trials of TPL and its derivatives. By critically evaluating the gap between TPL’s antitumor ability and clinical utility, we highlight both promising therapeutic avenues and persistent challenges in its development as a modern oncotherapeutic drug.

2. Plant TwHF Characteristics and Geographic Distribution

The plant TwHF (also known as Thunder God Vine) is a traditional Chinese botanical medicine, first documented in the Compendium of Materia Medica in the 16th century [1]. The plant’s Chinese name (Leigongteng) alludes to the plant’s potent toxicity. The plant is cultivated across Asia, including Korea, Japan, and India. TwHF was introduced to the United States in the 1930s and has since attracted research interest from scientists worldwide. This plant is a deciduous subshrub or a climbing semi-woody vine, and its root and rhizomes are highly important in traditional Chinese medicine. TwHF belongs to the genus Tripterygium (Celastraceae), which includes several closely related species, such as T. hypoglaucum and T. regelii [15], which are also toxic and exhibit similar antitumor and immunomodulatory effects.

3. Traditional Uses of TwHF and Chemical Structure of TPL

The traditional uses of TwHF were documented in Chinese medical literature as early as the Ming Dynasty. No non-Chinese medicinal use of TwHF was documented prior to modern times, likely due to its restricted geographical distribution. Given its significant toxicity, TwHF was traditionally applied topically rather than orally. A summary of its traditional uses is provided in Table 1.
In 1972, a compound called TPL was extracted from the roots of the TwHF plant [16]. X-ray crystallography showed that TPL consists of a 5/7/5 tricyclic diterpenoid canonical skeleton, a highly strained and reactive three-membered epoxy bridge (C-12/C-13), and a α,β-unsaturated five-membered lactone ring (Figure 1).
Table 1. Traditional uses of TwHF.
Table 1. Traditional uses of TwHF.
The Name or Origin of Traditional UsesMain ComponentsUsageReference
TwHFLeaves of TWHFItchy skin, external usehttps://www.hnysfww.com/mobile/goods.php?id=9024 (accessed on 12 November 2025)
TwHFFlower of TWHF, Lindera aggregata (Sims) KostermSkin sores, external usehttps://www.hnysfww.com/mobile/goods.php?id=9024 (accessed on 12 November 2025)
HUO BA HUA GEN TabletRoot of T. hypoglaucumPsoriasis, chronic nephritishttps://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI2MDMwNjE2NTI1NxIUemd6eHlqaHNienoyMDAzMDcwMTgaCGxiMmY4enkz (accessed on 12 November 2025)
https://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI2MDMwNjE2NTI1NxINemhwZjIwMDAwMjAzMhoIbHdxZ3g0bDQ%3D (accessed on 12 November 2025)
Tripterygium glycosides tabletsTripterygium glycosidesRheumatoid arthritis, nephrotic syndrome,https://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI2MDMwNjE2NTI1NxIUZ3VhbmdkeXh5eGIyMDAyMDMwMzYaCHN4OXhleXdq (accessed on 12 November 2025)
TwHF tabletsTriptolideRheumatoid arthritis, nephrotic syndrome, https://d.wanfangdata.com.cn/thesis/Ch1UaGVzaXNOZXdTb2xyOVMyMDI2MDExNzA4NTkxNhIHWTgwMzUzNRoIZDZkZmNuc3g%3D (accessed on 12 November 2025)
https://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI2MDMwNjE2NTI1NxINdGp6eTIwMjEwMjAxNhoINTR6aDV0d24%3D (accessed on 12 November 2025)
Jin Guan TabletsTwHF, Dipsacus asper Wall. ex Henry, Chinese yam, Asarum heterotropoides F. Schmidt, etc.Rheumatoid arthritis, ankylosing spondylitishttps://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI2MDMwNjE2NTI1NxIOenh5amgyMDA5MDIwMDIaCGtvcWpjemNy (accessed on 12 November 2025)
Shuangniu Trauma Medicinal WineRoot of TwHF, aconitum kusnezoffii, safflower, etc.Traumatic injuries, externalhttp://m.zhongyoo.com/yaojiu/5114.html (accessed on 12 November 2025)
Kidney disease prescriptionTwHF, Chrysanthemum, dandelion, bittercressNephrotic syndrome[17]
Anti-rheumatic wineTwHF, Clematis chinensis, Rehmannia root, Polygonatum sibiricumRheumatoid arthritishttps://d.wanfangdata.com.cn/periodical/CiBQZXJpb2RpY2FsQ0hJU29scjkyMDI2MDMwNjE2NTI1NxINaGJ6eTIwMDMwMzAwMxoIOG95bDVjOXQ%3D (accessed on 12 November 2025)
God’s Response All-Effective OintmentTwHF, Aconitum kusnezoffii, Linderae sibiricum, Areca catechuAll wind-induced swelling and toxic diseaseshttp://ethnobotany.cn/ (accessed on 12 November 2025)
InsecticideTwHFInsecticides to larva[18]

4. Pharmacology

4.1. Toxicity

The clinical application of TPL is limited by dose-limiting toxicities affecting the liver, kidneys, heart, reproductive system, and others (Figure 2). As the primary site of drug metabolism, the liver is particularly susceptible to toxicity from drugs and their metabolites. TPL-induced hepatotoxicity involves multiple intracellular signaling pathways, including the regulation of cytochrome P450 enzymes, immune cell responses, and gut microbiota imbalance. Specifically, TPL has been shown to cause hepatotoxicity by reducing the substrate affinity, activity, and expression (at both transcriptional and protein levels) of CYP450 isoforms, including 3A, 2C9, 2C19, and 2E1 [19,20,21]. Furthermore, TPL sensitizes hepatocytes to exogenous NK-cell-mediated cytotoxicity by inhibiting hepatocyte MHC-I expression [22]. Additionally, TPL-induced liver injury has been linked to Th2 cytokines produced by iNKT cells, which promote the expression of immunoregulatory factors [23]. TPL triggers iron accumulation and lipid peroxidation by modulating Nrf2 expression [24]. Interestingly, TPL perturbs the gut microbiota-bile acid-FXR axis, wherein a reduction in Lactobacillus rhamnosus GG abundance ultimately promotes liver damage [25].
The kidney is also highly vulnerable to TPL toxicity. Shen et al. demonstrated that the organic cation transporter 2, expressed on the surface of renal tubular epithelial cells, mediates TPL transfer from the blood to the renal tubule [26]. Within the tubule, TPL disrupts cell–cell junctions and increases paracellular permeability [27]. The principal mechanisms underlying TPL-induced nephrotoxicity are oxidative stress and inflammation, both of which are dose-dependent [28]. Multi-omics analyses have revealed changes in RNA and protein profiles, implicating several pathways in TPL nephrotoxicity. These include the cytochrome P450 protein family, cellular lipolytic activity, and antioxidant nuclear transcription factors, operating through acute-phase response signaling, the antigen presentation pathway, FXR/RXR activation, LPS/IL-1-mediated inhibition of RXR function, and EIF2 signaling [29,30]. Furthermore, an in vivo study confirmed that oxidative stress-induced mitochondrial DNA damage activates the cGAS-STING pathway, which leads to nephrotoxicity [28].
Research on TPL-induced cardiotoxicity emerged in the 2010s. A predominant finding is that metabolic dysregulation, implicated in approximately half of the related studies, impairs glucose uptake and glycogen metabolism [31,32]. This dysregulation promotes the generation of reactive oxygen species (ROS), inducing oxidative stress that damages cardiac mitochondria, proteins, and DNA through multiple pathways [33,34], ultimately leading to cardiomyocyte apoptosis and F-actin depolymerization [35]. Mechanistic studies have highlighted several key processes. The mitochondria-targeted antioxidant MitoQ was shown to alleviate TPL-induced cardiotoxicity by restoring NRF2 expression [36]. Similarly, calycosin, a compound known to regulate mitochondrial respiration via PGC-1α activation [37,38], protected against TPL-induced impairment of PGC-1α/NRF1-dependent mitochondrial biogenesis and respiration [39], suggesting a potential combination strategy to mitigate toxicity. Furthermore, Xu et al. used patch-clamp experiments to show that TPL binds to and inhibits the voltage-gated sodium channels Nav1.5 and Nav1.7, contributing to its cardiotoxic effects [40]. Additional reported mechanisms include SLC7A11/GPX4 inactivation-mediated ferroptosis and dysregulated autophagy [34,41,42].
TPL systemic toxicity has been studied in several preclinical in vivo models. In zebrafish embryos, TPL exposure caused a concentration-dependent reduction in mean swimming distance, suggesting neurobehavioral toxicity [43]. Paradoxically, other studies have reported neuroprotective effects in models of neurodegenerative diseases, attributed to its anti-inflammatory action on microglia [44,45]. In males, TPL caused significant testicular damage and impaired spermatogenesis. Reduced sperm concentration and aberrant morphology were evident. These effects were mediated by elevated ROS and malondialdehyde production, along with decreased glutathione levels and glutathione peroxidase 4 (GPX4) expression [46]. In females, TPL exposure diminished ovarian function and fertility, an effect driven by mitochondrial DNA release and subsequent activation of the cGAS-STING pathway [47]. Additionally, TPL administration perturbed the gut microbiota composition, notably reducing the abundance of Lactobacillus rhamnosus GG [25]. TPL also induced mitochondrial dysfunction and ROS production, causing systemic inflammatory responses in the kidney and liver [48], as well as in inner ear stem cells [49].

4.2. PK

A comprehensive review published in 2019 summarized the PK profile of TPL [50]. Briefly, TPL is rapidly and extensively absorbed after oral administration, exhibiting a bioavailability of approximately 75% in dogs and reaching peak plasma concentration (Tmax) within 10 min. Following oral dosing, TPL distributes extensively into major organs, including the liver, heart, spleen, lung, and kidney. TPL is metabolized primarily by human CYP2C19 and CYP3A4 enzymes, with less than 4% of the administered dose recovered unchanged in feces, bile, and urine within 24 h. It is eliminated rapidly, with reported terminal half-lives of 0.42 h (oral) and 0.19 h (intravenous) in rats. Notably, nearly 39% of the parent drug is cleared via biliary excretion post-absorption [50]. In 2020, Zhu et al. developed a strategy for synchronous measuring of TPL both in blood and brain based on mass spectrometry [51]. They found the Tmax to be 55.0 ± 12.3 min and Cmax of 15.1 ± 5.3 ng/mL after oral gavage 0.5 mg/kg for normal rats, and the area under the curve increased to 1.5-fold in rat models of Alzheimer’s disease.
Subsequent studies include TPL co-administration with paeoniflorin, the main active component of Paeonia lactiflora, which has anti-inflammatory properties, resulting in reduced peak concentration (Cmax) and delayed Tmax of TPL [52]. The uptake and efflux of TPL in the rat duodenum were shown to be mediated by Oatp1a5 and P-glycoprotein, respectively [53]. Pretreatment with antibiotics increased the Cmax and relative bioavailability of TPL by approximately 50%, attributable to an elevated inflammatory response [54].

4.3. Molecular Docking

Central to network pharmacology, molecular docking facilitates the discovery of novel therapeutic compounds, enables the molecular-level prediction of ligand–target interactions, and provides a framework for deciphering structure–activity relationships [55]. A number of studies have employed molecular docking to explore cross-targets and related pathways of TPL across different diseases [56]. Common targets of TPL identified in multiple studies include AKT1, TP53, CASP3, TNF and STAT3 [57,58,59,60]. In addition, the NF-kB pathway has been reported as a key TPL-regulated pathway [59,61,62].

5. TPL Derivations and Delivery System

5.1. Chemical Structure of TPL’s Derivation

Due to its significant systemic toxicity (described below) and poor aqueous solubility, numerous derivatives have been synthesized to overcome these limitations. To the best of our knowledge, at least 20 TPL derivatives with confirmed in vitro cytotoxic effects have been reported (Table 2). The paramount common advantages of these derivatives are reduced toxicity and improved solubility [63]. Beyond these shared benefits, several derivatives exhibit specific mechanistic advantages: TRC102 potently reduces tRXRα expression and inactivates AKT [64]; LLDT-8 and LLDT-67 demonstrate neuroprotective effects against ischemic injury and Parkinson’s disease, respectively [65,66]; and MRx102 downregulates XIAP and Mcl-1, inhibits RNA transcription, and suppresses the Wnt signaling pathway [67].

5.2. TPL Delivery

A 2019 review comprehensively summarized TPL delivery systems into five types: nanoparticle encapsulation, oligonucleotide, peptide, sugar, and antibody conjugates [68]. Herein, we review the progress achieved from 2019 (summarized in Table 2).
The field of nanomaterials has witnessed explosive growth in recent years, attracting extensive research interest. Exosomes, as endogenous delivery systems that have gained prominence in recent years, exhibit targeted effects, reduced toxicity, and immune evasion capabilities. Liu et al. were the first to construct a TPL-loaded exosome delivery system, demonstrating superior antitumor efficacy compared with free TPL, along with reduced liver and spleen toxicity [69]. Another report combined exosomes and liposomes with oligonucleotides to co-deliver miR-497 and TPL, overcoming cisplatin resistance in ovarian cancer by activating the PI3K/AKT/mTOR pathway [70]. Similarly, Gu et al. developed hybrid nanoparticles encapsulating exosomes, liposomes, and CYP3A4-siRNA, which effectively inhibited melanoma growth with negligible toxicity in a mouse model [71].
Recently, biomimetic nanoparticles have shown considerable potential in prolonging circulation time, enhancing membrane penetration, and improving the solubility and stability of loaded drugs. Li et al. developed cancer cell membrane-camouflaged biomimetic Poly(lactic-co-glycolic acid) (PLGA) nanoparticles loaded with TPL for the treatment of hepatocellular carcinoma (HCC), which promoted tumor-site accumulation and reduced TPL toxicity [72]. Another study utilized a cancer cell–platelet hybrid membrane to co-deliver sorafenib and TPL, leveraging the advantages of both long circulation and homologous targeting [73]. Metal–organic frameworks (MOFs) have recently emerged as promising drug-delivery platforms due to their tunable pore sizes, large surface areas, and ease of functionalization. In one study, a TPL-loaded MOF coated with methotrexate enabled effective tumor accumulation and deep penetration, thereby remodeling the tumor microenvironment in triple-negative breast cancer [74].
Table 2. The derivation and delivery system for TPL.
Table 2. The derivation and delivery system for TPL.
NameMolecular Formula *AdvantageReference
TPLCancers 18 01196 i001 [16]
ZT01Cancers 18 01196 i002Strong anti-inflammatory effects and low toxicity;
obviously beneficial effect on DSS-induced colitis		[75]
PG490-88 (Omtriptolide)Cancers 18 01196 i003 Highly effective in prevention of murine GVHD via inhibition of alloreactive T cell expansion through interleukin-2 production[76]
LLDT-8Cancers 18 01196 i004 Inhibits T cell activation;
reduces toxicity		[77]
LLDT-246Cancers 18 01196 i005Suppresses NF-κB signaling by interpreting AKT/GSK3β/mTOR pathway on HCT-116 cells[78]
LLDT-288Cancers 18 01196 i006Efficacy in human prostate xenograft mice model with obviously low toxicity; no inhibitory effects on CYP450 isoforms[79]
LLDT-67Cancers 18 01196 i007Neuroprotective effect: enhances NGF synthesis in astrocytes in the midbrain and rescue dopaminergic neurons indirectly through TrkA activation[65]
Epoxide-transposition analogues of triptolideCancers 18 01196 i008Cytotoxicity to A549+HT29[80]
MRx-102Not availableDecreased leukemia burden and increased survival time in mouse;
Inhibited Wnt pathway in lung cancer		[67,81]
TP-disulfide-CR7 (TP-S-S-CR7)Cancers 18 01196 i009Reduce toxicity to skin and organ;
No effect on the intracellular ROS;		[82]
Triptolidyl 2-(1-methylpiperidine-1-yl) acetate and a series of C-14 triptolide derivatives (17 types)Cancers 18 01196 i010Decreases toxicity and increases water solubility;
efficacy on imatinib-resistant CML		[83]
TRC4Cancers 18 01196 i011Decreases the nuclear retinoid X receptor-α;
inactivates AKT and induces apoptosis		[64]
TPL-memantineCancers 18 01196 i012Neuroprotective effect against Aβ1–42 toxicity;
inhibitory effect against LPS-induced TNF-α production		[84]
MinnelideCancers 18 01196 i013 Increases water solubility and bioavailability;
reduces systemic toxicity;
clinical trial for leukemia, pancreatic and gastric cancer		[2,85]
Tryptophan (Trp), Valine (Val), and Lysine (Lys) conjugated to TPLCancers 18 01196 i014Pancreatic-cancer-selective delivery system; increases cytotoxicity[86]
Triptolide aminoglycoside (TPAG)Cancers 18 01196 i015Increases kidney-targeting efficiency;
protective effect against renal ischemia/reperfusion injury;
low systemic toxicity		[87]
TP-CSOCancers 18 01196 i016Increases water solubility;
reduces systemic toxicity;
increases half-life in blood circulation		[3]
Cet-TPLCancers 18 01196 i017Target-specific cytotoxicity against EGFR-expressing cancer cells; reduced in vivo toxicity[88]
CCTPNot availableReduced in vivo toxicity[89]
CK21Cancers 18 01196 i018Inhibits NF-kB pathway;
increases intracellular ROS;
reduces toxicity in vivo		[90]
CL20Cancers 18 01196 i019Strong cytotoxicity to human hepatoma[91]
AS1411-triptolide conjugate (AS-TP)Cancers 18 01196 i020In situ triptolide release and increases intra-tumor triptolide accumulation; increases anti-TNBC efficacy and reduces in vivo toxicity[92]
TPL loaded nanoparticle platform composed of L-ascorbate palmitateNot available Increases water solubility;
reduces systemic toxicity;
inhibits the erosion of synovitis and bone tissue		[93]
TP-PEG-SS assembled with ginsenoside Rg3 and lecithin to form nanovesiclesCancers 18 01196 i021Targets mitochondria and M2 macrophage;
selectively accumulates in the tumor;
improves the immunosuppressive tumor microenvironment		[94]
Functionally modified triptolide liposome (FA+TPP-TP-Lips)Cancers 18 01196 i022Accumulates in tumor tissues;
improves their targeted delivery to mitochondria;
reduces systemic toxicity		[95]
TP-P1Cancers 18 01196 i023Improves water solubility and rapid release;
inhibits acute myeloid leukemia in vivo;
enhances the efficacy of FLT3 inhibitors		[96]
TPDMSACancers 18 01196 i024Suppresses influenza A virus replication and regulates innate immune response[97]
TPL@TFBFNot available Triggers systemic antitumor immune responses;
induces ferroptosis and pyroptosis;
synthetic effects when combined with immune checkpoint blockade		[98]
A10 (one silyl ether-based linker conjugated with antibody drug)Cancers 18 01196 i025Targeted cytotoxicity for cells with high PD-L1 expression;
bystander killing effect on cells with low PD-L1 expression;
accumulates in tumor tissues		[99]
C60-SMEDDS/TPNot availableReduces toxicity to normal tissues[100]
Na2GA&TP-BMNot availableIncreases cytotoxicity to tumor cells;
increases water solubility;
extends the blood circulation time with less system toxicity		[101]
TP-siRC@tHyNPsNot availableEnhances targeted delivery through DR5 receptor; prolongs the half-life of TP and decreases its in vivo toxicity[71]
TriptolidiolCancers 18 01196 i026NLRP3 inhibitor;
regulates inflammasome assembly and activation by decreasing K63-linked ubiquitination		[102]
TP-DEA2Cancers 18 01196 i027Improves water solubility; reduces toxicity; inhibits pulmonary fibrosis by reducing the secretion of a-SMA in fibroblasts[103]
A9 (TPO–furoxan conjugation)Cancers 18 01196 i028Enhances water solubility and safety;
integrates NO-mediated ROS induction and FOCM inhibition		[104]
TP-PSPNot availableKidney-targeted delivery;
enhances water solubility and reduces renal, cardiac, gastrointestinal, and hepatic toxicity		[105]
STP1Cancers 18 01196 i029Modulates the differentiation of B cells into plasma cells and T cells into Tfh cells; regulates B-cell receptor and T-cell receptor signaling by directly targeting Fyn kinase[106]
* The molecular formula were adopted from the corresponding references.

6. The Antitumor Mechanism and Preclinical Studies of TPL

6.1. XPB and RPB1 Are the Major Targets of TPL

Multiple studies have shown that TPL inhibits de novo RNA synthesis, suggesting that RNA polymerases might be the target. However, the precise mechanisms were only elucidated recently (Figure 3). Titov et al. demonstrated that TPL covalently binds to XPB, a subunit of transcription factor TFIIH, thereby inhibiting its DNA-dependent ATPase activity [5]. In parallel, TPL induces rapid depletion of RPB1, the main subunit of RNA polymerase II, which is a hallmark of transcription elongation blockage. This is accompanied by Ser-5 hyperphosphorylation and increased ubiquitination within the RPB1 C-terminal domain [107,108]. Together, these two mechanisms inhibit the transcriptional activation of several transcription factors, including NF-κB, AP-1, p53, and HSF-1, ultimately leading to apoptosis and cell death.

6.2. Glioma

Glioma is a common intracranial malignant tumor characterized by high incidence, rapid progression, frequent recurrence, and poor prognosis. Over the past two decades, TPL has demonstrated promising potential in preclinical glioma models in vitro [109]. Subsequent studies have shown that TPL induces glioma cell apoptosis by modulating the NF-κB signaling pathway and promoting ROS generation [61]. In IDH1-mutant supratentorial gliomas, TPL disrupts glutathione metabolism, establishing a synthetic lethality with ROS [110]. Furthermore, TPL counteracts the immunosuppressive tumor microenvironment by reversing glioma-mediated inhibition of CD4+ T cells and promoting IFN-γ secretion, highlighting its immunomodulatory function [111].
TPL also enhances the radiosensitivity of glioma cells in vitro, suggesting a potential role as a radiosensitizer for high-grade gliomas [112]. When injected, TPL-preloaded hydrogel applied to the resected glioblastoma cavity demonstrated marked antitumor efficacy via ferroptosis and prolonged survival in an orthotopic relapse model [113]. Similarly, a dendrimer–TPL conjugate designed to target tumor-associated macrophages has also been shown to reduce tumor burden with minimal systemic exposure [114]. MicroRNA let-7b-5p has been identified as an important mediator of TPL’s anti-glioma activity [115].

6.3. Pancreatic Tumor

Pancreatic cancer, a highly aggressive malignancy, remains a paramount challenge in oncology. Current chemotherapeutic options are limited by their efficacy and selectivity. Recent efforts have focused on developing TPL-based prodrugs to improve TPL’s therapeutic profile. Wang et al. developed antibody–drug conjugates incorporating TPL via silyl ether linkers, which enhanced tumor-targeted cytotoxicity and demonstrated potent bystander-killing effects [99]. In a multifaceted approach, TPL prodrug nanovesicles co-loaded with ginsenoside Rg3 were designed to simultaneously target tumor mitochondria and reprogram immunosuppressive M2 macrophages, thereby remodeling the tumor microenvironment and reducing tumor burden in vivo [94]. Similarly, Lycium barbarum polysaccharide-modified selenium nanoparticles encapsulating TPL were shown to reduce systemic toxicity and enhance solubility [116]. To improve water solubility and therapeutic efficacy, Su et al. conjugated TPL to octreotide using a linker derived from succinic anhydride [117]. Beyond delivery systems, a novel TPL analog was designed to inhibit the NF-κB pathway, increase oxidative phosphorylation, and induce mitochondrial-mediated apoptosis [90]. Moser et al. identified TPL as a covalent inhibitor of XPB, demonstrating that it disrupts the TFIIH complex, induces RPB1 degradation, and synergizes with TRAIL to promote apoptosis [118]. TPL and its prodrug Minnelide exert antitumor effects by targeting the cell cycle, super-enhancers, the SP1 transcription factor, and the RAS signaling pathway in pancreatic in vivo models [119,120,121,122].

6.4. Leukemia

Leukemia comprises a heterogeneous group of hematological malignancies driven by genetic and epigenetic dysregulation. As leukemic cells are systemically distributed, the development of targeted delivery systems for TPL has received comparatively less attention than in solid tumors. Nevertheless, Kang et al. synthesized a series of water-soluble TPL prodrugs that exhibited faster and more complete release profiles than Minnelide and effectively suppressed leukemia growth in vivo [96]. Most research has centered on combination therapies and overcoming chemoresistance. TPL has been shown to potentiate the efficacy of various agents, including the BET inhibitor JQ1, the Bcl-2 inhibitor ABT-199, the XPO1 inhibitor selinexor, idarubicin, and Ara-C, through distinct synergistic pathways [4,123,124,125,126]. Furthermore, TPL can reverse chemoresistance, notably to adriamycin, by promoting ROS generation and disrupting the DNA damage response [126,127,128]. Apoptosis is a major antitumor mechanism of TPL in leukemia. Multiple signaling pathways and mechanisms mediate TPL’s proapoptotic effect. TPL induced apoptosis in leukemia cells by activating ROCK1 and phosphorylating MLC and MYPT1. Minnelide has also been extensively investigated. It induces apoptosis and cell cycle arrest by targeting the Ars2/miR-190a-3p/Akt pathway and downregulating the transcriptional regulator c-Myc, thereby inhibiting the growth of patient-derived leukemia cells in both in vitro and in vivo models [129,130].

6.5. Lung Cancer

Non-small-cell lung cancer (NSCLC), the most prevalent form of lung cancer, has been the subject of substantial research interest regarding the therapeutic potential of TPL. Initial investigations date back to 2002, when Lee et al. demonstrated that TPL sensitizes NSCLC cells to TRAIL-induced apoptosis by inhibiting NF-κB activation [131]. Subsequent studies have elucidated multiple molecular targets of TPL. It induced apoptosis and exerted antimetastatic effects by targeting the MAPK-ERK and MAPK-MKP pathways [132,133]. Furthermore, TPL activates ERK1/2 to stabilize p53, which in turn inhibits IκBα phosphorylation and NF-κB nuclear translocation, thereby blocking NF-κB-mediated survival signaling in NSCLC cells [134]. This downregulation of NF-κB can reverse paclitaxel resistance, a key mechanism of treatment failure [135]. Mechanistically, TPL also inhibits the PI3K/AKT pathway by reducing the expression of PFKFB2, a critical glycolytic enzyme required for cell growth [136,137]. Additionally, TPL directly binds to HNF1A, thereby attenuating the Sonic Hedgehog pathway and overcoming paclitaxel resistance [138]. From an immunotherapeutic perspective, TPL downregulates PD-L1 expression on NSCLC cells by suppressing the IFN-γ-JAK-STAT signaling axis, suggesting a potential role in modulating immune checkpoint inhibition [139]. It is noteworthy that, to the best of our knowledge, no studies have yet been published on the efficacy of TPL against small-cell lung cancer.

6.6. Other Cancers

TPL has demonstrated efficacy against a broad spectrum of other cancers in vitro and in vivo, often through shared pathways. For instance, a C60-modified self-micro-emulsifying drug-delivery system for TPL exhibited reduced cytotoxicity against normal cells compared with liver and gastric cancer cells in vitro [100]. Similarly, various TPL-loaded nanoplatforms have been developed for esophageal, hepatocellular, breast, and gastric cancers, demonstrating improved biosafety and enhanced on-target efficacy [140,141,142,143]. Mechanistically, TPL induces gastric cancer cell apoptosis by covalently binding to PRDX2, thereby elevating intracellular ROS levels [144]. In the context of cancer immunotherapy, TPL downregulates PD-L1 expression and suppresses the IFN-γ-mediated JAK2-STAT1 pathway in oral cancer [145]. Furthermore, TPL modulates different forms of cell death and stress responses. It induces cuproptosis, a novel copper-dependent cell death linked to metabolism, in cervical cancer by regulating the XIAP/COMMD1/ATP7A/B axis [146].

7. Clinical Trial

A systematic search of clinical trial registries, including the NIH clinical trial (https://clinicaltrials.gov), the European clinical trial (https://euclinicaltrials.eu/, accessed on 17 November 2025), and the Chinese clinical trial registry (https://www.chictr.org.cn/index.html, accessed on 17 November 2025), identified nine registered clinical trials investigating TPL (specifically its prodrug, Minnelide) for oncological indications, all listed on the NIH platform (Table 3). Among these, four trials have been completed, half of which were Phase I studies. Two Phase I trials conducted by the same research group demonstrated the safety and preliminary efficacy of Minnelide in patients with advanced gastrointestinal cancers [147,148]. One Phase II trial (NCT03117920) focusing on refractory pancreatic cancer was completed in 2023, but no results have been reported in the registry or in peer-reviewed publications. Another Phase II trial (NCT04896073) reported its outcomes: of the 16 enrolled patients, 12 completed the study. Grade 4 adverse events, primarily hematological (e.g., anemia, thrombocytopenia, leukopenia), occurred in 8.7–25% of patients, with no grade 5 events reported. Critically, no objective responses (complete or partial) were observed, and the median overall survival was 4.91 months (95% CI: 1.96–7.85). Currently, three Phase I trials for advanced NSCLC, pancreatic cancer, and solid tumors are in the recruitment phase, while one trial for acute myeloid leukemia was terminated due to dose-limiting toxicities (NCT03760523). Although preclinical studies continue to support Minnelide’s potential in other malignancies [2,85,130], its clinical translation requires further optimization. Notably, a growing body of research into novel TPL conjugates and delivery systems has shown superior preclinical profiles (Table 2), suggesting promising alternatives for future clinical development.
Table 3. The clinical trials associated with TPL in oncology.
Table 3. The clinical trials associated with TPL in oncology.
IDTitleTumor TypePhaseInterventionStatusConclusionReference *
NCT04896073Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the PancreasAdvanced Refractory Adenosquamous Carcinoma of the PancreasIIMinnelideCompletedPlatform data without publication. A total of 16 patients were enrolled and 12 patients completed the trial. The investigator provided baseline characteristics including age, sex, ethnicity, race, and region. In term of side effects, 8.7–25% patients showed grade 4 side effects, mainly related to blood cell (anemia, platelet and white blood cell) count decrease, without grade 5 side effects. However, most importantly, neither patient showed complete response nor partial response. Overall survival found to be 4.91 (1.96–7.85) months.[149]
NCT03117920A Phase II, International Open Label Trial of Minnelide in Patients with Refractory Pancreatic CancerRefractory Pancreatic CancerIIMinnelideCompletedNo results posted on the platform or publication.ClinicalTrials.gov (NCT03117920)
NCT05566834Minnelide Capsules Alone and in Combination with Paclitaxel in Advanced Gastric Cancer (AGC)Advanced Gastric CancerIMinnelideCompletedMinnelide alone at a dose of 1.25 mg was tolerable for AGC patients and the combination of Minnelide and paclitaxel exhibited meaningful clinical efficacy alongside a manageable safety profile.[147]
NCT01927965Study of Minnelide in Patients with Advanced GI TumorsAdvanced Gastrointestinal CarcinomaIMinnelideCompletedThe trial identified a dose and schedule of Minnelide in patients with refractory GI cancers and observed efficacy of Minnelide treatment. Grade ≥ 3 toxicities occurred in 69% of patients; the most common side effect was neutropenia (38%).[148]
NCT05166616Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-small-cell Lung CancerAdvanced EGFR Mutated NSCLCIbMinnelide + osimertinibRecruiting ClinicalTrials.gov (NCT05166616)
NCT03129139A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide Capsules Given Alone or in Combination with Protein-Bound Paclitaxel in Patients With Advanced Solid TumorsAdvanced Solid TumorsIMinnelideRecruiting ClinicalTri-als.gov (NCT03129139)
NCT05557851Minnelide Along with Abraxane Plus Gemcitabine in Patients With Metastatic Adenocarcinoma of the PancreasMetastatic Adenocarcinoma of the PancreasIbMinnelide + Abraxane + gemcitabineRecruiting ClinicalTri-als.gov (NCT05557851)
NCT03760523Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Acute Myeloid LeukemiaIMinnelideTerminatedTwo dose-limiting toxicity events occurred.ClinicalTri-als.gov (NCT03760523)
NCT03347994Minnelide in Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)Relapsed or Refractory AMLIMinnelideWithdrawnDiscordance in contractual language and terms.ClinicalTri-als.gov (NCT03347994)
* Completed trials with published results are cited by reference numbers; ongoing or completed trials without published results are referenced by their ClinicalTrials.gov identifier.

8. Conclusions

Despite its broad biological activities, including antitumor, anti-inflammatory, immunosuppressive, and neuroprotective effects, the clinical application of TPL is significantly limited by its systemic toxicity [150,151,152]. To overcome this challenge, numerous derivatives and drug-delivery systems have been developed to mitigate toxicity and enhance on-target efficacy. Among them, Minnelide, a water-soluble prodrug derived from TPL by adding a phosphate group, has emerged as one of the most promising candidates and has been widely evaluated in clinical trials owing to its reduced toxicity [85]. According to major clinical trial registries, Minnelide has been involved in nine trials across several malignancies, including leukemia, pancreatic, gastric, and lung cancers. Importantly, Minnelide has demonstrated an acceptable safety profile in patients, with the main adverse event being reversible acute cerebellar toxicity. However, since Minnelide is reconverted to TPL by phosphatases in vivo, it does not fully resolve either the compound’s inherent toxicity or its on-target effect [85]. Consequently, alternative delivery strategies using novel materials, including MOF, PLGA nanoparticles, and cancer cell–platelet hybrid membranes, have been explored [72,73,74]. Nevertheless, their clinical translation remains hampered by challenges in production costs, quality control, biocompatibility, and potential long-term toxicity.
Alternatively, combination therapy is a viable strategy for reducing the required doses of individual drugs, targeting multiple mechanisms, delaying the development of resistance, and improving therapeutic efficacy [153]. Given the systemic toxicity observed in DMG preclinical models, alternative combination therapies remain a promising approach to enhance the clinical profile of TPL. Such prospective combinations may provide the opportunity to reduce TPL toxicity by using a lower dose of the drug.

Author Contributions

Conception and design: Y.G. and J.N., Initial draft: Y.G., Critical review of the work and manuscript: B.K. and J.N., Final approval of manuscript: all authors. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by funding from the Swiss Government Excellence Scholarship (No. 2025-0047), ChadTough Defeat DIPG Foundation (Saline, MI, USA), Isabella Kerr Family fund, Lilabean Foundation (Four Corners, MD, USA), National Institutes of Health (NIH; grant CA266596), Swiss to Cure DIPG Foundation (Dübendorf, Switzerland), Swiss National Science Foundation (SNSF; grants CRSII5-198739 and 320030-227900), Rising Tide Foundation (Schaffhausen, Switzerland; grant CCR-20-500), Avery’s Little Army, and the Yuvaan Tiwari Foundation (Atlanta, GA, USA) funds.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to our review.

Acknowledgments

Figure 2 and Figure 3 were created by the authors using BioRender.com under an academic license.

Conflicts of Interest

The authors declare no conflicts of interest.

Abbreviations

The following abbreviations are used in this manuscript:
TPLtriptolide
ROSreactive oxygen species
GPX4glutathione peroxidase 4
PKpharmacokinetic
DMGdiffuse midline glioma
Cmaxmaximum concentration
Tmaxtime to maximum concentration
TwHFTripterygium wilfordii Hook. f.
HCChepatocellular carcinoma
MOFsmetal–organic frameworks
NSCLCnon-small-cell lung cancer
PLGAPoly (lactic-co-glycolic acid)
TFtranscription factor
AGCadvanced gastric cancer
AMLacute myeloid leukemia

References

  1. Tao, X.; Lipsky, P.E. The Chinese Anti-Inflammatory and Immunosuppressive Herbal Remedy Tripterygium wilfordii Hook F. Rheum. Dis. Clin. North Am. 2000, 26, 29–50. [Google Scholar] [CrossRef]
  2. Rodriguez-Blanco, J.; Salvador, A.D.; Suter, R.K.; Swiderska-Syn, M.; Palomo-Caturla, I.; Kliebe, V.; Shahani, P.; Peterson, K.; Turos-Cabal, M.; Vieira, M.E.; et al. Triptolide and Its Prodrug Minnelide Target High-Risk Myc-Amplified Medulloblastoma in Preclinical Models. J. Clin. Investig. 2024, 134, e171136. [Google Scholar] [CrossRef] [PubMed]
  3. Wang, X.; Zeng, H.; Zhu, X.; Xu, D.; Tian, Q.; Wang, C.; Zhao, L.; Zhao, J.; Miao, M.; Wu, X. TP-CSO: A Triptolide Prodrug for Pancreatic Cancer Treatment. Molecules 2022, 27, 3686. [Google Scholar] [CrossRef]
  4. Shi, Y.F.; Liu, L.; He, L.L.; Ye, J.; Lin, Z.J.; Yuan, D.L.; Deng, M.M.; Fang, Z.H.; Carter, B.Z.; Xu, B. Combining Triptolide with Abt-199 Is Effective against Acute Myeloid Leukemia through Reciprocal Regulation of Bcl-2 Family Proteins and Activation of the Intrinsic Apoptotic Pathway. Cell Death Dis. 2020, 11, 555. [Google Scholar] [CrossRef]
  5. Titov, D.V.; Gilman, B.; He, Q.L.; Bhat, S.; Low, W.K.; Dang, Y.; Smeaton, M.; Demain, A.L.; Miller, P.S.; Kugel, J.F.; et al. Xpb, a Subunit of Tfiih, Is a Target of the Natural Product Triptolide. Nat. Chem. Biol. 2011, 7, 182–188. [Google Scholar] [CrossRef] [PubMed]
  6. Hou, W.; Liu, B.; Xu, H. Triptolide: Medicinal Chemistry, Chemical Biology and Clinical Progress. Eur. J. Med. Chem. 2019, 176, 378–392. [Google Scholar] [CrossRef] [PubMed]
  7. Li, M.; Li, J.; Tang, Q.; Zhu, Y. Potential Antitumor Activity of Triptolide and Its Derivatives: Focused on Gynecological and Breast Cancers. Biomed. Pharmacother. 2024, 180, 117581. [Google Scholar] [CrossRef]
  8. Cui, D.; Zhang, C.; Zhang, L.; Zheng, J.; Wang, J.; He, L.; Jin, H.; Kang, Q.; Zhang, Y.; Li, N.; et al. Natural Anti-Cancer Products: Insights from Herbal Medicine. Chin. Med. 2025, 20, 82. [Google Scholar] [CrossRef]
  9. Feng, K.; Li, X.; Bai, Y.; Zhang, D.; Tian, L. Mechanisms of Cancer Cell Death Induction by Triptolide: A Comprehensive Overview. Heliyon 2024, 10, e24335. [Google Scholar] [CrossRef]
  10. AbdulHussein, A.H.; Al-Taee, M.M.; Radih, Z.A.; Aljuboory, D.S.; Mohammed, Z.Q.; Hashesh, T.S.; Riadi, Y.; Hadrawi, S.K.; Najafi, M. Mechanisms of Cancer Cell Death Induction by Triptolide. Biofactors 2023, 49, 718–735. [Google Scholar] [CrossRef]
  11. Xu, T.; Zhu, Y.; Ge, S.; Liu, S.B. The Roles of Tpl in Hematological Malignancies. Hematology 2023, 28, 2231765. [Google Scholar] [CrossRef]
  12. Cui, D.; Xu, D.; Yue, S.; Yan, C.; Liu, W.; Fu, R.; Ma, W.; Tang, Y. Recent Advances in the Pharmacological Applications and Liver Toxicity of Triptolide. Chem. Biol. Interact. 2023, 382, 110651. [Google Scholar] [CrossRef] [PubMed]
  13. He, X.; Wang, N.; Zhang, Y.; Huang, X.; Wang, Y. The Therapeutic Potential of Natural Products for Treating Pancreatic Cancer. Front. Pharmacol. 2022, 13, 1051952. [Google Scholar] [CrossRef] [PubMed]
  14. Wei, J.; Yan, Y.; Chen, X.; Qian, L.; Zeng, S.; Li, Z.; Dai, S.; Gong, Z.; Xu, Z. The Roles of Plant-Derived Triptolide on Non-Small Cell Lung Cancer. Oncol. Res. 2019, 27, 849–858. [Google Scholar] [CrossRef] [PubMed]
  15. Liu, C.; Wang, J.; Ko, Y.Z.; Shiao, M.S.; Wang, Y.; Sun, J.; Yuan, Q.; Wang, L.; Chiang, Y.C.; Guo, L. Genetic Diversities in Wild and Cultivated Populations of the Two Closely-Related Medical Plants Species, Tripterygium wilfordii and T. Hypoglaucum (Celastraceae). BMC Plant Biol. 2024, 24, 195. [Google Scholar] [CrossRef]
  16. Kupchan, S.M.; Court, W.A.; Dailey, R.G., Jr.; Gilmore, C.J.; Bryan, R.F. Triptolide and Tripdiolide, Novel Antileukemic Diterpenoid Triepoxides from Tripterygium wilfordii. J. Am. Chem. Soc. 1972, 94, 7194–7195. [Google Scholar] [CrossRef]
  17. Chen, Y.; Gong, Z.; Chen, X.; Tang, L.; Zhao, X.; Yuan, Q.; Cai, G. Tripterygium wilfordii Hook F (a Traditional Chinese Medicine) for Primary Nephrotic Syndrome. Cochrane Database Syst. Rev. 2013, 2013, CD008568. [Google Scholar] [CrossRef]
  18. Luo, D.Q.; Zhang, X.; Tian, X.; Liu, J.K. Insecticidal Compounds from Tripterygium wilfordii Active against Mythimna Separata. Z. Naturforsch. C J. Biosci. 2004, 59, 421–426. [Google Scholar] [CrossRef]
  19. Jiang, H.Y.; Bao, Y.N.; Lin, F.M.; Jin, Y. Triptolide Regulates Oxidative Stress and Inflammation Leading to Hepatotoxicity Via Inducing Cyp2e1. Hum. Exp. Toxicol. 2021, 40, S775–S787. [Google Scholar] [CrossRef]
  20. Lu, Y.; Xie, T.; Zhang, Y.; Zhou, F.; Ruan, J.; Zhu, W.; Zhu, H.; Feng, Z.; Zhou, X. Triptolide Induces Hepatotoxicity Via Inhibition of Cyp450s in Rat Liver Microsomes. BMC Complement. Altern. Med. 2017, 17, 15. [Google Scholar] [CrossRef]
  21. Xiao, X.; Zhang, T.; Huang, J.; Zhao, Q.; Li, F. Effect of Cyp3a4 on Liver Injury Induced by Triptolide. Biomed. Chromatogr. 2020, 34, e4864. [Google Scholar] [CrossRef] [PubMed]
  22. Zhang, H.; Yuan, Z.; Wang, J.; Tang, Q.; Miao, Y.; Yuan, Z.; Huang, X.; Zhu, Y.; Nong, C.; Zhang, L.; et al. Triptolide Leads to Hepatic Intolerance to Exogenous Lipopolysaccharide and Natural-Killer-Cell Mediated Hepatocellular Damage by Inhibiting Mhc Class I Molecules. Phytomedicine 2023, 109, 154621. [Google Scholar] [CrossRef]
  23. Zou, M.; Nong, C.; Yu, Z.; Cai, H.; Jiang, Z.; Xue, R.; Huang, X.; Sun, L.; Zhang, L.; Wang, X. The Role of Invariant Natural Killer T Cells and Associated Immunoregulatory Factors in Triptolide-Induced Cholestatic Liver Injury. Food Chem. Toxicol. 2020, 146, 111777. [Google Scholar] [CrossRef] [PubMed]
  24. Guo, L.; Yang, Y.; Ma, J.; Xiao, M.; Cao, R.; Xi, Y.; Li, T.; Huang, T.; Yan, M. Triptolide Induces Hepatotoxicity by Promoting Ferroptosis through Nrf2 Degradation. Cell Biol. Toxicol. 2024, 40, 94. [Google Scholar] [CrossRef] [PubMed]
  25. Hu, S.; Tang, B.; Lu, C.; Wang, S.; Wu, L.; Lei, Y.; Tang, L.; Zhu, H.; Wang, D.; Yang, S. Lactobacillus Rhamnosus Gg Ameliorates Triptolide-Induced Liver Injury through Modulation of the Bile Acid-Fxr Axis. Pharmacol. Res. 2024, 206, 107275. [Google Scholar] [CrossRef]
  26. Shen, Q.; Wang, J.; Yuan, Z.; Jiang, Z.; Shu, T.; Xu, D.; He, J.; Zhang, L.; Huang, X. Key Role of Organic Cation Transporter 2 for the Nephrotoxicity Effect of Triptolide in Rheumatoid Arthritis. Int. Immunopharmacol. 2019, 77, 105959. [Google Scholar] [CrossRef]
  27. Sun, L.; Li, H.; Huang, X.; Wang, T.; Zhang, S.; Yang, J.; Huang, S.; Mei, H.; Jiang, Z.; Zhang, L. Triptolide Alters Barrier Function in Renal Proximal Tubular Cells in Rats. Toxicol. Lett. 2013, 223, 96–102. [Google Scholar] [CrossRef]
  28. Lu, J.; Zhang, Y.; Dong, H.; Sun, J.; Zhu, L.; Liu, P.; Wen, F.; Lin, R. New Mechanism of Nephrotoxicity of Triptolide: Oxidative Stress Promotes Cgas-Sting Signaling Pathway. Free Radic. Biol. Med. 2022, 188, 26–34. [Google Scholar] [CrossRef]
  29. Li, M.; Hu, T.; Tie, C.; Qu, L.; Zheng, H.; Zhang, J. Quantitative Proteomics and Targeted Fatty Acids Analysis Reveal the Damage of Triptolide in Liver and Kidney. Proteomics 2017, 17, 1700001. [Google Scholar] [CrossRef]
  30. Li, J.; Jin, J.; Li, M.; Guan, C.; Wang, W.; Zhu, S.; Qiu, Y.; Huang, M.; Huang, Z. Role of Nrf2 in Protection against Triptolide-Induced Toxicity in Rat Kidney Cells. Toxicol. Lett. 2012, 213, 194–202. [Google Scholar] [CrossRef] [PubMed]
  31. Wang, W.; Yang, Y.; Xiong, Z.; Kong, J.; Fu, X.; Shen, F.; Huang, Z. Inhibition of Glycogen Synthase Kinase 3beta Ameliorates Triptolide-Induced Acute Cardiac Injury by Desensitizing Mitochondrial Permeability Transition. Toxicol. Appl. Pharmacol. 2016, 313, 195–203. [Google Scholar] [CrossRef] [PubMed]
  32. Xi, Y.; Zhang, Y.; Pan, J.; Chen, S.; Lu, S.; Shen, F.; Huang, Z. Triptolide Dysregulates Glucose Uptake Via Inhibition of Ikkbeta-Nf-Kappab Pathway by P53 Activation in Cardiomyocytes. Toxicol. Lett. 2020, 318, 1–11. [Google Scholar] [CrossRef]
  33. Xi, Y.; Wang, W.; Wang, L.; Pan, J.; Cheng, Y.; Shen, F.; Huang, Z. Triptolide Induces P53-Dependent Cardiotoxicity through Mitochondrial Membrane Permeabilization in Cardiomyocytes. Toxicol. Appl. Pharmacol. 2018, 355, 269–285. [Google Scholar] [CrossRef]
  34. Yang, Y.; Wang, W.; Xiong, Z.; Kong, J.; Qiu, Y.; Shen, F.; Huang, Z. Activation of Sirt3 Attenuates Triptolide-Induced Toxicity through Closing Mitochondrial Permeability Transition Pore in Cardiomyocytes. Toxicol. In Vitro 2016, 34, 128–137. [Google Scholar] [CrossRef] [PubMed]
  35. Qi, X.M.; Zhang, W.Z.; Zuo, Y.Q.; Qiao, Y.B.; Zhang, Y.L.; Ren, J.H.; Li, Q.S. Nrf2/Nrf1 Signaling Activation and Crosstalk Amplify Mitochondrial Biogenesis in the Treatment of Triptolide-Induced Cardiotoxicity Using Calycosin. Cell Biol. Toxicol. 2024, 41, 2. [Google Scholar] [CrossRef]
  36. Tan, G.; Qin, Z.; Jiang, S.; Zhang, L.; Zhang, G.; Huang, M.; Huang, Z.; Jin, J. Mitoq Alleviates Triptolide-Induced Cardiotoxicity Via Activation of P62/Nrf2 Axis in H9c2 Cells. Toxicol. In Vitro 2023, 86, 105487. [Google Scholar] [CrossRef]
  37. Huang, C.; Xue, L.F.; Hu, B.; Liu, H.H.; Huang, S.B.; Khan, S.; Meng, Y. Calycosin-Loaded Nanoliposomes as Potential Nanoplatforms for Treatment of Diabetic Nephropathy through Regulation of Mitochondrial Respiratory Function. J. Nanobiotechnol. 2021, 19, 178. [Google Scholar] [CrossRef]
  38. An, F.; Zhao, R.; Xuan, X.; Xuan, T.; Zhang, G.; Wei, C. Calycosin Ameliorates Advanced Glycation End Product-Induced Neurodegenerative Changes in Cellular and Rat Models of Diabetes-Related Alzheimer’s disease. Chem. Biol. Interact. 2022, 368, 110206. [Google Scholar] [CrossRef]
  39. Qi, X.M.; Qiao, Y.B.; Zhang, Y.L.; Wang, A.C.; Ren, J.H.; Wei, H.Z.; Li, Q.S. Pgc-1alpha/Nrf1-Dependent Cardiac Mitochondrial Biogenesis: A Druggable Pathway of Calycosin against Triptolide Cardiotoxicity. Food Chem. Toxicol. 2023, 171, 113513. [Google Scholar] [CrossRef]
  40. Xu, Y.; Li, W.; Wen, R.; Sun, J.; Liu, X.; Zhao, S.; Zhang, J.; Liu, Y.; Zhao, M. Voltage-Gated Sodium Channels, Potential Targets of Tripterygium wilfordii Hook. F. To Exert Activity and Produce Toxicity. J. Ethnopharmacol. 2023, 311, 116448. [Google Scholar] [CrossRef] [PubMed]
  41. Liu, X.; Chen, C.; Han, D.; Zhou, W.; Cui, Y.; Tang, X.; Xiao, C.; Wang, Y.; Gao, Y. Slc7a11/Gpx4 Inactivation-Mediated Ferroptosis Contributes to the Pathogenesis of Triptolide-Induced Cardiotoxicity. Oxid. Med. Cell Longev. 2022, 2022, 3192607. [Google Scholar] [CrossRef]
  42. Wang, S.R.; Chen, X.; Ling, S.; Ni, R.Z.; Guo, H.; Xu, J.W. Microrna Expression, Targeting, Release Dynamics and Early-Warning Biomarkers in Acute Cardiotoxicity Induced by Triptolide in Rats. Biomed. Pharmacother. 2019, 111, 1467–1477. [Google Scholar] [CrossRef] [PubMed]
  43. Romero, N.G.; Gutierrez, G.; Teixido, E.; Li, L.; Klose, J.; Leung, P.C.; Canigueral, S.; Fritsche, E.; Barenys, M. Developmental Neurotoxicity Evaluation of Three Chinese Herbal Medicines in Zebrafish Larvae by Means of Two Behavioral Assays: Touch-Evoked Response and Light/Dark Transition. Reprod. Toxicol. 2023, 121, 108469. [Google Scholar] [CrossRef] [PubMed]
  44. Huang, Y.Y.; Zhang, Q.; Zhang, J.N.; Zhang, Y.N.; Gu, L.; Yang, H.M.; Xia, N.; Wang, X.M.; Zhang, H. Triptolide up-Regulates Metabotropic Glutamate Receptor 5 to Inhibit Microglia Activation in the Lipopolysaccharide-Induced Model of Parkinson’s Disease. Brain Behav. Immun. 2018, 71, 93–107. [Google Scholar] [CrossRef]
  45. Gao, J.P.; Sun, S.; Li, W.W.; Chen, Y.P.; Cai, D.F. Triptolide Protects against 1-Methyl-4-Phenyl Pyridinium-Induced Dopaminergic Neurotoxicity in Rats: Implication for Immunosuppressive Therapy in Parkinson’s Disease. Neurosci. Bull. 2008, 24, 133–142. [Google Scholar] [CrossRef] [PubMed]
  46. Li, J.; Chen, D.; Suo, J.; Li, J.; Zhang, Y.; Wang, Y.; Deng, Z.; Zhang, Q.; Ma, B. Triptolide Induced Spermatogenesis Dysfunction Via Ferroptosis Activation by Promoting K63-Linked Gpx4 Polyubiquitination in Spermatocytes. Chem. Biol. Interact. 2024, 399, 111130. [Google Scholar] [CrossRef] [PubMed]
  47. Cheng, S.Y.; Yang, Y.F.; Wang, Y.L.; Yue, Z.P.; Chen, Y.Z.; Wang, W.K.; Xu, Z.R.; Li, L.F.; Shen, H.; Qi, Z.M.; et al. Triptolide Exposure Triggers Ovarian Inflammation by Activating Cgas-Sting Pathway and Decrease Oocyte Quality in Mouse. Food Chem. Toxicol. 2025, 196, 115201. [Google Scholar] [CrossRef]
  48. Zhang, H.R.; Li, Y.P.; Shi, Z.J.; Liang, Q.Q.; Chen, S.Y.; You, Y.P.; Yuan, T.; Xu, R.; Xu, L.H.; Ouyang, D.Y.; et al. Triptolide Induces Panoptosis in Macrophages and Causes Organ Injury in Mice. Apoptosis 2023, 28, 1646–1665. [Google Scholar] [CrossRef]
  49. Tang, X.; Wang, C.; Hsieh, Y.; Wang, C.; Wang, J.; Han, Z.; Cong, N.; Ma, R.; Chi, F. Triptolide Induces Toxicity in Inner Ear Stem Cells Via Promoting DNA Damage. Toxicol. In Vitro 2019, 61, 104597. [Google Scholar] [CrossRef]
  50. Song, W.; Liu, M.; Wu, J.; Zhai, H.; Chen, Y.; Peng, Z. Preclinical Pharmacokinetics of Triptolide: A Potential Antitumor Drug. Curr. Drug Metab. 2019, 20, 147–154. [Google Scholar] [CrossRef]
  51. Zhu, S.; Wang, X.; Zheng, Z.; Zhao, X.E.; Bai, Y.; Liu, H. Synchronous Measuring of Triptolide Changes in Rat Brain and Blood and Its Application to a Comparative Pharmacokinetic Study in Normal and Alzheimer’s Disease Rats. J. Pharm. Biomed. Anal. 2020, 185, 113263. [Google Scholar] [CrossRef] [PubMed]
  52. Guan, Y.M.; Shen, Q.; He, L.F.; Chen, L.M.; Zang, Z.; Liu, L.; Zhu, W.F.; Li-Hua, C.; Liu, H.N. Pharmacokinetics and Tissue Distribution of Combined Triptolide and Paeoniflorin Regimen for Percutaneous Administration in Rats Assessed by Liquid Chromatography-Tandem Mass Spectrometry. Evid. Based Complement. Alternat Med. 2021, 2021, 8864273. [Google Scholar] [CrossRef] [PubMed]
  53. Guo, Z.; Wang, H.; Sun, J.; Ma, Y.; Cui, X.; Kou, S.; Jiang, Z.; Zhang, L.; Wang, X.; Wang, T.; et al. The Intestinal Absorption of Triptolide for the Treatment of Rheumatoid Arthritis Is Mediated by Transporters. Int. Immunopharmacol. 2024, 143, 113440. [Google Scholar] [CrossRef]
  54. Liu, Y.T.; Hu, Y.Q.; Wang, Y.L.; Huang, K.; Chen, G.F.; Zhou, H.; Liu, C.H.; Yang, T. Antibiotic Pretreatment Promotes Orally-Administered Triptolide Absorption and Aggravates Hepatotoxicity and Intestinal Injury in Mice. J. Ethnopharmacol. 2022, 292, 115224. [Google Scholar] [CrossRef]
  55. Pinzi, L.; Rastelli, G. Molecular Docking: Shifting Paradigms in Drug Discovery. Int. J. Mol. Sci. 2019, 20, 4331. [Google Scholar] [CrossRef]
  56. Zhai, M.; Chen, T.; Shao, M.; Yang, X.; Qi, Y.; Kong, S.; Jiang, L.; Yang, E. Unveiling the Molecular Mechanisms of Haitang-Xiaoyin Mixture in Psoriasis Treatment Based on Bioinformatics, Network Pharmacology, Machine Learning, and Molecular Docking Verification. Comput. Biol. Chem. 2025, 115, 108352. [Google Scholar] [CrossRef] [PubMed]
  57. An, X.; Fan, D.; Yin, Z.; Zhang, J.; Zhou, Y.; Tian, R.; Yan, M. Prediction of the Potential Mechanism of Triptolide in Improving Diabetic Nephropathy by Utilizing a Network Pharmacology and Molecular Docking Approach. Front. Biosci. (Landmark Ed.) 2022, 27, 94. [Google Scholar] [CrossRef]
  58. Zhu, W.; Li, Y.; Zhao, J.; Wang, Y.; Li, Y.; Wang, Y. The Mechanism of Triptolide in the Treatment of Connective Tissue Disease-Related Interstitial Lung Disease Based on Network Pharmacology and Molecular Docking. Ann. Med. 2022, 54, 541–552. [Google Scholar] [CrossRef]
  59. Song, X.; Zhang, Y.; Dai, E.; Wang, L.; Du, H. Prediction of Triptolide Targets in Rheumatoid Arthritis Using Network Pharmacology and Molecular Docking. Int. Immunopharmacol. 2020, 80, 106179. [Google Scholar] [CrossRef]
  60. Shen, J.; Fang, Y.; Xu, N.; Chen, H.; Zhu, M.; Li, D.; Chu, Z.; Sunagawa, M.; Liu, Y.; Wang, H.; et al. Exploring the Mechanism of Triptolide Inhibiting the Motility of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis Via Rhoa/Rho-Associated Kinase Axis, Based on Network Pharmacology, Molecular Docking and Molecular Dynamics Simulations. Front. Pharmacol. 2025, 16, 1545514. [Google Scholar] [CrossRef] [PubMed]
  61. Li, X.; Shan, Y.; Wang, S.; Wang, J.; Heng, X. Triptolide Induces Apoptosis of Glioma Cells by Inhibiting Nf-Kappab Activation During Oxidative Stressv. Sci. Rep. 2024, 14, 29740. [Google Scholar] [CrossRef]
  62. Seo, E.J.; Dawood, M.; Hult, A.K.; Olsson, M.L.; Efferth, T. Network Pharmacology of Triptolide in Cancer Cells: Implications for Transcription Factor Binding. Investig. New Drugs 2021, 39, 1523–1537. [Google Scholar] [CrossRef]
  63. Noel, P.; Von Hoff, D.D.; Saluja, A.K.; Velagapudi, M.; Borazanci, E.; Han, H. Triptolide and Its Derivatives as Cancer Therapies. Trends Pharmacol. Sci. 2019, 40, 327–341. [Google Scholar] [CrossRef]
  64. Wang, P.Y.; Zeng, W.J.; Liu, J.; Wu, Y.L.; Ma, Y.; Zeng, Z.; Pang, J.Y.; Zhang, X.K.; Yan, X.; Wong, A.S.T.; et al. Trc4, an Improved Triptolide Derivative, Specifically Targets to Truncated Form of Retinoid X Receptor-Alpha in Cancer Cells. Biochem. Pharmacol. 2017, 124, 19–28. [Google Scholar] [CrossRef]
  65. Wu, D.D.; Huang, L.; Zhang, L.; Wu, L.Y.; Li, Y.C.; Feng, L. Lldt-67 Attenuates Mptp-Induced Neurotoxicity in Mice by up-Regulating Ngf Expression. Acta Pharmacol. Sin. 2012, 33, 1187–1194. [Google Scholar] [CrossRef]
  66. Chen, Y.; Zhang, L.; Ni, J.; Wang, X.; Cheng, J.; Li, Y.; Zhen, X.; Cao, T.; Jia, J. Lldt-8 Protects against Cerebral Ischemia/Reperfusion Injury by Suppressing Post-Stroke Inflammation. J. Pharmacol. Sci. 2016, 131, 131–137. [Google Scholar] [CrossRef] [PubMed]
  67. Carter, B.Z.; Mak, D.H.; Shi, Y.; Fidler, J.M.; Chen, R.; Ling, X.; Plunkett, W.; Andreeff, M. Mrx102, a Triptolide Derivative, Has Potent Antileukemic Activity in Vitro and in a Murine Model of Aml. Leukemia 2012, 26, 443–450. [Google Scholar] [CrossRef] [PubMed]
  68. Xu, H.; Liu, B. Triptolide-Targeted Delivery Methods. Eur. J. Med. Chem. 2019, 164, 342–351. [Google Scholar] [CrossRef] [PubMed]
  69. Liu, H.; Shen, M.; Zhao, D.; Ru, D.; Duan, Y.; Ding, C.; Li, H. The Effect of Triptolide-Loaded Exosomes on the Proliferation and Apoptosis of Human Ovarian Cancer Skov3 Cells. Biomed. Res. Int. 2019, 2019, 2595801. [Google Scholar] [CrossRef]
  70. Li, L.; He, D.; Guo, Q.; Zhang, Z.; Ru, D.; Wang, L.; Gong, K.; Liu, F.; Duan, Y.; Li, H. Exosome-Liposome Hybrid Nanoparticle Codelivery of Tp and Mir497 Conspicuously Overcomes Chemoresistant Ovarian Cancer. J. Nanobiotechnology 2022, 20, 50. [Google Scholar] [CrossRef]
  71. Gu, Y.; Li, A.; Zeng, Y.; He, M.; Qi, F.; Liu, R.; Cai, H.; Li, D.; Tang, X.; Fu, Z.; et al. Engineering Hybrid Nanoparticles for Targeted Codelivery of Triptolide and Cyp3a4-Sirna against Pulmonary Metastatic Melanoma. Sci. Adv. 2025, 11, eadv6990. [Google Scholar] [CrossRef] [PubMed]
  72. Li, Z.; Lan, J.; Wu, Y.; Ding, Y.; Zhang, T. Homotypic Cell Membrane-Camouflaged Biomimetic Plga Nanoparticle Loading Triptolide for the Treatment of Hepatocellular Carcinoma. Drug Deliv. 2024, 31, 2354687. [Google Scholar] [CrossRef]
  73. Li, Z.; Yang, G.; Han, L.; Wang, R.; Gong, C.; Yuan, Y. Sorafenib and Triptolide Loaded Cancer Cell-Platelet Hybrid Membrane-Camouflaged Liquid Crystalline Lipid Nanoparticles for the Treatment of Hepatocellular Carcinoma. J. Nanobiotechnol. 2021, 19, 360. [Google Scholar] [CrossRef]
  74. Wu, H.; Jin, M.; Liu, Y.; Wang, S.; Liu, C.; Quan, X.; Jin, M.; Gao, Z.; Jin, Y. A Self-Targeting Mofs Nanoplatform for Treating Metastatic Triple-Negative Breast Cancer through Tumor Microenvironment Remodeling and Chemotherapy Potentiation. Int. J. Pharm. 2024, 664, 124625. [Google Scholar] [CrossRef]
  75. Fu, J.; Zang, Y.; Zhou, Y.; Chen, C.; Shao, S.; Shi, G.; Wu, L.; Zhu, G.; Sun, T.; Zhang, D.; et al. Exploring a Novel Triptolide Derivative Possess Anti-Colitis Effect Via Regulating T Cell Differentiation. Int. Immunopharmacol. 2021, 94, 107472. [Google Scholar] [CrossRef]
  76. Chen, B.J.; Liu, C.; Cui, X.; Fidler, J.M.; Chao, N.J. Prevention of Graft-Versus-Host Disease by a Novel Immunosuppressant, Pg490-88, through Inhibition of Alloreactive T Cell Expansion. Transplantation 2000, 70, 1442–1447. [Google Scholar] [CrossRef]
  77. Fu, Y.F.; Zhu, Y.N.; Ni, J.; Zhong, X.G.; Tang, W.; Zhou, R.; Zhou, Y.; Dong, J.R.; He, P.L.; Wan, H.; et al. (5r)-5-Hydroxytriptolide (Lldt-8), a Novel Triptolide Derivative, Prevents Experimental Autoimmune Encephalomyelitis Via Inhibiting T Cell Activation. J. Neuroimmunol. 2006, 175, 142–151. [Google Scholar] [CrossRef]
  78. Li, M.; Wang, X.; Liu, M.; Qi, X.; Li, J. Nf-Kappab Signaling Inhibition and Anticancer Activities of Lldt-246 on Human Colorectal Cancer Hct-116 Cells in Vitro. Biomed. Pharmacother. 2014, 68, 527–535. [Google Scholar] [CrossRef]
  79. Xu, H.; Fan, X.; Zhang, G.; Liu, X.; Li, Z.; Li, Y.; Jiang, B. Lldt-288, a Novel Triptolide Analogue Exhibits Potent Antitumor Activity in Vitro and in Vivo. Biomed. Pharmacother. 2017, 93, 1004–1009. [Google Scholar] [CrossRef] [PubMed]
  80. Aoyagi, Y.; Hitotsuyanagi, Y.; Hasuda, T.; Fukaya, H.; Takeya, K.; Aiyama, R.; Matsuzaki, T.; Hashimoto, S. Semisynthesis of C-Ring Modified Triptolide Analogues and Their Cytotoxic Activities. Bioorg. Med. Chem. Lett. 2006, 16, 1947–1949. [Google Scholar] [CrossRef] [PubMed]
  81. Reno, T.A.; Tong, S.W.; Wu, J.; Fidler, J.M.; Nelson, R.; Kim, J.Y.; Raz, D.J. The Triptolide Derivative Mrx102 Inhibits Wnt Pathway Activation and Has Potent Anti-Tumor Effects in Lung Cancer. BMC Cancer 2016, 16, 439. [Google Scholar] [CrossRef] [PubMed]
  82. Tian, T.; Song, Y.; Li, K.; Sun, Y.; Wang, Q. Synthesis, Characterization, and Evaluation of Triptolide Cell-Penetrating Peptide Derivative for Transdermal Delivery of Triptolide. Mol. Pharm. 2018, 15, 560–570. [Google Scholar] [CrossRef] [PubMed]
  83. Xu, F.; Shi, X.; Li, S.; Cui, J.; Lu, Z.; Jin, Y.; Lin, Y.; Pang, J.; Pan, J. Design, Synthesis, and Biological Evaluation of Novel Water-Soluble Triptolide Derivatives: Antineoplastic Activity against Imatinib-Resistant Cml Cells Bearing T315i Mutant Bcr-Abl. Bioorg. Med. Chem. 2010, 18, 1806–1815. [Google Scholar] [CrossRef] [PubMed]
  84. Ning, C.; Mo, L.; Chen, X.; Tu, W.; Wu, J.; Hou, S.; Xu, J. Triptolide Derivatives as Potential Multifunctional Anti-Alzheimer Agents: Synthesis and Structure-Activity Relationship Studies. Bioorg. Med. Chem. Lett. 2018, 28, 689–693. [Google Scholar] [CrossRef]
  85. Chugh, R.; Sangwan, V.; Patil, S.P.; Dudeja, V.; Dawra, R.K.; Banerjee, S.; Schumacher, R.J.; Blazar, B.R.; Georg, G.I.; Vickers, S.M.; et al. A Preclinical Evaluation of Minnelide as a Therapeutic Agent against Pancreatic Cancer. Sci. Transl. Med. 2012, 4, 156ra139. [Google Scholar] [CrossRef]
  86. Lou, D.; Lou, Z.; Lin, Y.; Shangguan, H.; Lin, Y.; Luo, Q.; Zhang, H.; Lin, G.; Chen, R.; Kou, L.; et al. Atb(0,+)-Targeted Delivery of Triptolide Prodrugs for Safer and More Effective Pancreatic Cancer Therapy. Bioorg. Med. Chem. Lett. 2021, 33, 127728. [Google Scholar] [CrossRef]
  87. Qi, B.; Wang, X.; Zhou, Y.; Han, Q.; He, L.; Gong, T.; Sun, X.; Fu, Y.; Zhang, Z. A Renal-Targeted Triptolide Aminoglycoside (Tpag) Conjugate for Lowering Systemic Toxicities of Triptolide. Fitoterapia 2015, 103, 242–251. [Google Scholar] [CrossRef] [PubMed]
  88. Zhang, K.; Ma, Y.; Guo, Y.; Sun, T.; Wu, J.; Pangeni, R.P.; Lin, M.; Li, W.; Horne, D.; Raz, D.J. Cetuximab-Triptolide Conjugate Suppresses the Growth of Egfr-Overexpressing Lung Cancers through Targeting RNA Polymerase II. Mol. Ther. Oncolytics 2020, 18, 304–316. [Google Scholar] [CrossRef]
  89. Zeng, H.; Zhu, X.; Tian, Q.; Yan, Y.; Zhang, L.; Yan, M.; Li, R.; Li, X.; Wang, G.; Ma, J.; et al. In Vivo Antitumor Effects of Carboxymethyl Chitosan-Conjugated Triptolide after Oral Administration. Drug Deliv. 2020, 27, 848–854. [Google Scholar] [CrossRef]
  90. Tian, Q.; Zhang, P.; Wang, Y.; Si, Y.; Yin, D.; Weber, C.R.; Fishel, M.L.; Pollok, K.E.; Qiu, B.; Xiao, F.; et al. A Novel Triptolide Analog Downregulates Nf-Kappab and Induces Mitochondrial Apoptosis Pathways in Human Pancreatic Cancer. eLife 2023, 12, e85862. [Google Scholar] [CrossRef]
  91. Cheng, C.; Li, G.; Zheng, G.; Yu, C. Design and Synthesis of Cinnamic Acid Triptolide Ester Derivatives as Potent Antitumor Agents and Their Biological Evaluation. Bioorg. Med. Chem. Lett. 2022, 67, 128760. [Google Scholar] [CrossRef]
  92. Chen, Y.; Yang, J.; Wang, C.; Wang, T.; Zeng, Y.; Li, X.; Zuo, Y.; Chen, H.; Zhang, C.; Cao, Y.; et al. Aptamer-Functionalized Triptolide with Release Controllability as a Promising Targeted Therapy against Triple-Negative Breast Cancer. J. Exp. Clin. Cancer Res. 2024, 43, 207. [Google Scholar] [CrossRef]
  93. Li, M.; Wang, G.; Yan, Y.; Jiang, M.; Wang, Z.; Zhang, Z.; Wu, X.; Zeng, H. Triptolide and L-Ascorbate Palmitate Co-Loaded Micelles for Combination Therapy of Rheumatoid Arthritis and Side Effect Attenuation. Drug Deliv. 2022, 29, 2751–2758. [Google Scholar] [CrossRef] [PubMed]
  94. Wang, J.; Cui, J.; Chen, Y.; Zhou, H.; Li, X.; Wu, X.; Zhou, R.; Zeng, H. Self-Assembled Triptolide Prodrug Nanovesicles Loading with Ginsenoside Rg3 for Double-Targeted Therapy of Pancreatic Cancer. Mater. Today Bio 2025, 33, 102004. [Google Scholar] [CrossRef]
  95. Zhou, L.; Du, Y.; Shang, Y.; Xiang, D.; Xia, X. A Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma. Int. J. Nanomed. 2024, 19, 12975–12998. [Google Scholar] [CrossRef] [PubMed]
  96. Kang, D.; Pan, X.; Song, Y.; Liu, Y.; Wang, D.; Zhu, X.; Wang, J.; Hu, L. Discovery of a Novel Water-Soluble, Rapid-Release Triptolide Prodrug with Improved Drug-Like Properties and High Efficacy in Human Acute Myeloid Leukemia. Eur. J. Med. Chem. 2022, 243, 114694. [Google Scholar] [CrossRef] [PubMed]
  97. Jiang, N.; Quan, L.; Zhou, Y.; Cheng, Y.; Li, H.; Chen, X.; Li, R.; Liu, D. Exploring the Anti-Influenza Virus Activity of Novel Triptolide Derivatives Targeting Nucleoproteins. Bioorg Chem. 2022, 129, 106118. [Google Scholar] [CrossRef]
  98. Wang, S.; Guo, Q.; Xu, R.; Lin, P.; Deng, G.; Xia, X. Combination of Ferroptosis and Pyroptosis Dual Induction by Triptolide Nano-Mofs for Immunotherapy of Melanoma. J. Nanobiotechnol. 2023, 21, 383. [Google Scholar] [CrossRef]
  99. Wang, H.; Huangfu, S.; Wei, D.; Sun, Z.; Wu, Y.; Yu, X.; Jiang, B.; Chen, H. Triptolide-Based Cleavable Antibody-Drug Conjugates for Pancreatic Cancer. Eur. J. Med. Chem. 2025, 295, 117798. [Google Scholar] [CrossRef]
  100. Xu, B.; Wang, Z.; Zhang, H.; Xu, X.; Tang, M.; Wang, G.; Ding, Z.; Yu, R.; Ding, M.; Zhang, T.; et al. The Cytoprotective Effect of C60 Derivatives in the Self-Microemulsifying Drug Delivery System against Triptolide-Induced Cytotoxicity in Vitro. Molecules 2024, 29, 4073. [Google Scholar] [CrossRef]
  101. Zhu, D.; Zhang, Q.; Chen, Y.; Xie, M.; Li, J.; Yao, S.; Li, M.; Lou, Z.; Cai, Y.; Sun, X. Mechanochemical Preparation of Triptolide-Loaded Self-Micelle Solid Dispersion with Enhanced Oral Bioavailability and Improved Anti-Tumor Activity. Drug Deliv. 2022, 29, 1398–1408. [Google Scholar] [CrossRef]
  102. Ding, M.Y.; Ning, C.; Chen, S.R.; Yin, H.R.; Xu, J.; Wang, Y. Discovery of Natural Product Derivative Triptolidiol as a Direct Nlrp3 Inhibitor by Reducing K63-Specific Ubiquitination. Br. J. Pharmacol. 2025, 182, 4876–4893. [Google Scholar] [CrossRef]
  103. Chen, Y.; Liang, M.; Li, W.; Yang, Z.; Yan, X.; Wu, L.; Yu, Q.; Chen, Y.; Chen, Y.; Xu, Y.; et al. Water-Soluble and Predictable-Release Triptolide Prodrugs Block Bleomycin-Induced Pulmonary Fibrosis in Mice. Eur. J. Med. Chem. 2024, 279, 116839. [Google Scholar] [CrossRef]
  104. Tian, Y.; Guan, J.; Luo, H.; Ning, Q.; Yang, X.; Ma, J.; Zang, Y.; Li, C.; Lai, F.; Zhang, D. Novel Nitric Oxide-Releasing Triptolidenol Derivatives Suppress Gastric Cancer by Targeting the Folate One-Carbon Metabolism Pathway and Inducing Ros Accumulation. Eur. J. Med. Chem. 2026, 309, 118772. [Google Scholar] [CrossRef] [PubMed]
  105. Qiao, P.; Chen, S.; Zhao, M.; Ju, Z.; Chen, J.; Xu, W.; Mao, L. Polygonatum Sibiricum Polysaccharide-Based Novel Triptolide Delivery Derived from Classic Compatibility Principles in Traditional Chinese Medicine: Simultaneous Renal Protection and Toxicity Attenuation in Diabetic Nephropathy. Int. J. Biol. Macromol. 2026, 349, 150848. [Google Scholar] [CrossRef]
  106. Ding, Q.Y.; Zhou, Y.; Luo, H.W.; Wei, Y.Z.; Feng, Y.F.; Zhang, D.M.; Wu, L.; Chen, C.J.; Zang, Y.D.; Zhang, T.T. Triptolide Derivative Stp1 Ameliorates Murine Systemic Lupus Erythematosus Via Targeting Fyn Kinase. Acta Pharmacol. Sin. 2026. [Google Scholar] [CrossRef]
  107. Vispe, S.; DeVries, L.; Creancier, L.; Besse, J.; Breand, S.; Hobson, D.J.; Svejstrup, J.Q.; Annereau, J.P.; Cussac, D.; Dumontet, C.; et al. Triptolide Is an Inhibitor of RNA Polymerase I and II-Dependent Transcription Leading Predominantly to Down-Regulation of Short-Lived mRNA. Mol. Cancer Ther. 2009, 8, 2780–2790. [Google Scholar] [CrossRef]
  108. Manzo, S.G.; Zhou, Z.L.; Wang, Y.Q.; Marinello, J.; He, J.X.; Li, Y.C.; Ding, J.; Capranico, G.; Miao, Z.H. Natural Product Triptolide Mediates Cancer Cell Death by Triggering Cdk7-Dependent Degradation of RNA Polymerase II. Cancer Res. 2012, 72, 5363–5373. [Google Scholar] [CrossRef] [PubMed]
  109. Lin, J.; Chen, L.; Lin, Z.; Zhao, M. Inhibitory Effect of Triptolide on Glioblastoma Multiforme in Vitro. J. Int. Med. Res. 2007, 35, 490–496. [Google Scholar] [CrossRef] [PubMed]
  110. Yu, D.; Liu, Y.; Zhou, Y.; Ruiz-Rodado, V.; Larion, M.; Xu, G.; Yang, C. Triptolide Suppresses Idh1-Mutated Malignancy Via Nrf2-Driven Glutathione Metabolism. Proc. Natl. Acad. Sci. USA 2020, 117, 9964–9972. [Google Scholar] [CrossRef]
  111. Zhang, L.; Yu, J.S. Triptolide Reverses Helper T Cell Inhibition and Down-Regulates Ifn-Gamma Induced Pd-L1 Expression in Glioma Cell Lines. J. Neuro-Oncol. 2019, 143, 429–436. [Google Scholar] [CrossRef]
  112. Shu, M.; Li, C.; Zhong, C.; Huang, T.; Wang, X.; Tan, Y.; Zhao, W.; Xie, X. Effects of Triptolide on Radiosensitivity of Human Glioma Cells and Its Mechanism. J. BUON 2021, 26, 1549–1555. [Google Scholar]
  113. Wu, H.; Cao, P.; Wang, H.; Wang, W.; Yu, H.; You, C.; Shen, T.; Yang, S.; Hu, Z.; Zhou, T.; et al. Postoperative Injection of a Triptolide-Preloaded Hydrogel Prevents the Recurrence of Glioblastoma by Dual-Pathway Activation of Ferroptosis. Small 2024, 20, e2406036. [Google Scholar] [CrossRef] [PubMed]
  114. Liaw, K.; Sharma, R.; Sharma, A.; Salazar, S.; Appiani La Rosa, S.; Kannan, R.M. Systemic Dendrimer Delivery of Triptolide to Tumor-Associated Macrophages Improves Anti-Tumor Efficacy and Reduces Systemic Toxicity in Glioblastoma. J. Control. Release 2021, 329, 434–444. [Google Scholar] [CrossRef]
  115. Liu, X.; Zhao, P.; Du, X.; Hou, J.; Zhang, G.; Zhang, W.; Yang, L.; Chen, Y. Let-7b-5p Promotes Triptolide-Induced Growth-Inhibiting Effects in Glioma by Targeting Igf1r. Naunyn Schmiedebergs Arch. Pharmacol. 2024, 397, 5909–5925. [Google Scholar] [CrossRef]
  116. Li, X.; Su, Y.; Lin, N.; Chen, Y.; Li, Z.; Zhang, Z.; Zhao, X.; Zeng, H. Lycium barbarum Polysaccharide-Stabilized Selenium Nanoparticles Deliver Triptolide to Induce Apoptosis for Pancreatic Cancer in Vitro and in Vivo. ACS Omega 2025, 10, 17108–17122. [Google Scholar] [CrossRef] [PubMed]
  117. Su, D.; Bao, Q.; Wang, X.; Qian, J.; Zhang, M.; Chen, J.; Wu, X. Sstr-Mediated Precision Delivery: Overcoming Triptolide’s Limitations through Octreotide Conjugation in Pancreatic Cancer Treatment. ACS Med. Chem. Lett. 2025, 16, 1048–1057. [Google Scholar] [CrossRef] [PubMed]
  118. Moser, R.; Annis, J.; Nikolova, O.; Whatcott, C.; Gurley, K.; Mendez, E.; Moran-Jones, K.; Dorrell, C.; Sears, R.C.; Kuo, C.; et al. Pharmacologic Targeting of Tfiih Suppresses Kras-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with Trail. Cancer Res. 2022, 82, 3375–3393. [Google Scholar] [CrossRef]
  119. Modi, S.; Giri, B.; Gupta, V.K.; Lavania, S.; Sethi, V.; Sharma, N.S.; Pandey, S.; Vickers, S.; Dudeja, V.; Saluja, A.K. Minnelide Synergizes with Conventional Chemotherapy by Targeting Both Cancer and Associated Stroma Components in Pancreatic Cancer. Cancer Lett. 2022, 537, 215591. [Google Scholar] [CrossRef]
  120. Noel, P.; Hussein, S.; Ng, S.; Antal, C.E.; Lin, W.; Rodela, E.; Delgado, P.; Naveed, S.; Downes, M.; Lin, Y.; et al. Triptolide Targets Super-Enhancer Networks in Pancreatic Cancer Cells and Cancer-Associated Fibroblasts. Oncogenesis 2020, 9, 100. [Google Scholar] [CrossRef]
  121. Kim, S.T.; Kim, S.Y.; Lee, J.; Kim, K.; Park, S.H.; Park, Y.S.; Lim, H.Y.; Kang, W.K.; Park, J.O. Triptolide as a Novel Agent in Pancreatic Cancer: The Validation Using Patient Derived Pancreatic Tumor Cell Line. BMC Cancer 2018, 18, 1103. [Google Scholar] [CrossRef]
  122. McGinn, O.; Gupta, V.K.; Dauer, P.; Arora, N.; Sharma, N.; Nomura, A.; Dudeja, V.; Saluja, A.; Banerjee, S. Inhibition of Hypoxic Response Decreases Stemness and Reduces Tumorigenic Signaling Due to Impaired Assembly of Hif1 Transcription Complex in Pancreatic Cancer. Sci. Rep. 2017, 7, 7872. [Google Scholar] [CrossRef]
  123. Liu, Y.; Chen, F.; Wang, S.; Guo, X.; Shi, P.; Wang, W.; Xu, B. Low-Dose Triptolide in Combination with Idarubicin Induces Apoptosis in Aml Leukemic Stem-Like Kg1a Cell Line by Modulation of the Intrinsic and Extrinsic Factors. Cell Death Dis. 2013, 4, e948. [Google Scholar] [CrossRef]
  124. Deng, M.; Huang, P.; Wang, L.; Jiang, Y.; Guo, Z.; Duan, H.; Zha, J.; Zhao, H.; Li, G.; Xu, B. The Synergy of Tpl and Selinexor in Mll-R Acute Myeloid Leukemia Via Rap1/Raf/Mek Pathway-Mediated Myc Downregulation. Transl. Oncol. 2025, 57, 102399. [Google Scholar] [CrossRef]
  125. Shi, Y.; Zhao, H.; Ye, J.; Li, Z.; Deng, M.; Zha, J.; Zhou, Y.; Zeng, H.; Lin, Y.; Pu, X.; et al. Low-Dose Triptolide Enhances Antitumor Effect of Jq1 on Acute Myeloid Leukemia through Inhibiting RNA Polymerase II in Vitro and in Vivo. Mol. Carcinog. 2020, 59, 1076–1087. [Google Scholar] [CrossRef]
  126. Pigneux, A.; Mahon, F.X.; Uhalde, M.; Jeanneteau, M.; Lacombe, F.; Milpied, N.; Reiffers, J.; Belloc, F. Triptolide Cooperates with Chemotherapy to Induce Apoptosis in Acute Myeloid Leukemia Cells. Exp. Hematol. 2008, 36, 1648–1659. [Google Scholar] [CrossRef] [PubMed]
  127. Zhao, H.; Shi, P.; Deng, M.; Jiang, Z.; Li, Y.; Kannappan, V.; Wang, W.; Li, P.; Xu, B. Low Dose Triptolide Reverses Chemoresistance in Adult Acute Lymphoblastic Leukemia Cells Via Reactive Oxygen Species Generation and DNA Damage Response Disruption. Oncotarget 2016, 7, 85515–85528. [Google Scholar] [CrossRef] [PubMed]
  128. Li, H.; Hui, L.; Xu, W.; Shen, H.; Chen, Q.; Long, L.; Zhu, X. Modulation of P-Glycoprotein Expression by Triptolide in Adriamycin-Resistant K562/A02 Cells. Oncol. Lett. 2012, 3, 485–489. [Google Scholar] [CrossRef] [PubMed]
  129. Yuan, L.; Jiang, X.; Jia, G.; Li, Z.; Wang, M.; Hu, S.; Yang, J.; Liang, F.; Zhang, F.; Gao, L.; et al. Minnelide Exhibits Antileukemic Activity by Targeting the Ars2/Mir-190a-3p Axis. Phytomedicine 2024, 130, 155724. [Google Scholar] [CrossRef]
  130. Giri, B.; Gupta, V.K.; Yaffe, B.; Modi, S.; Roy, P.; Sethi, V.; Lavania, S.P.; Vickers, S.M.; Dudeja, V.; Banerjee, S.; et al. Pre-Clinical Evaluation of Minnelide as a Therapy for Acute Myeloid Leukemia. J. Transl. Med. 2019, 17, 163. [Google Scholar] [CrossRef]
  131. Lee, K.Y.; Park, J.S.; Jee, Y.K.; Rosen, G.D. Triptolide Sensitizes Lung Cancer Cells to Tnf-Related Apoptosis-Inducing Ligand (Trail)-Induced Apoptosis by Inhibition of Nf-Kappab Activation. Exp. Mol. Med. 2002, 34, 462–468. [Google Scholar] [CrossRef]
  132. Tai, C.J.; Wu, A.T.; Chiou, J.F.; Jan, H.J.; Wei, H.J.; Hsu, C.H.; Lin, C.T.; Chiu, W.T.; Wu, C.W.; Lee, H.M.; et al. The Investigation of Mitogen-Activated Protein Kinase Phosphatase-1 as a Potential Pharmacological Target in Non-Small Cell Lung Carcinomas, Assisted by Non-Invasive Molecular Imaging. BMC Cancer 2010, 10, 95. [Google Scholar] [CrossRef]
  133. Meng, G.; Wang, W.; Chai, K.; Yang, S.; Li, F.; Jiang, K. Combination Treatment with Triptolide and Hydroxycamptothecin Synergistically Enhances Apoptosis in A549 Lung Adenocarcinoma Cells through Pp2a-Regulated Erk, P38 Mapks and Akt Signaling Pathways. Int. J. Oncol. 2015, 46, 1007–1017. [Google Scholar] [CrossRef]
  134. Zheng, L.; Jia, J.; Dai, H.; Wan, L.; Liu, J.; Hu, L.; Zhou, M.; Qiu, M.; Chen, X.; Chang, L.; et al. Triptolide-Assisted Phosphorylation of P53 Suppresses Inflammation-Induced Nf-Kappab Survival Pathways in Cancer Cells. Mol. Cell Biol. 2017, 37, e00149-17. [Google Scholar] [CrossRef]
  135. Jiang, N.; Dong, X.P.; Zhang, S.L.; You, Q.Y.; Jiang, X.T.; Zhao, X.G. Triptolide Reverses the Taxol Resistance of Lung Adenocarcinoma by Inhibiting the Nf-Kappab Signaling Pathway and the Expression of Nf-Kappab-Regulated Drug-Resistant Genes. Mol. Med. Rep. 2016, 13, 153–159. [Google Scholar] [CrossRef]
  136. Ren, J.; Zhao, S.; Lai, J. Triptolide Restrains the Growth, Invasion, Stemness, and Glycolysis of Non-Small Cell Lung Cancer Cells by Pfkfb2-Mediated Pi3k/Akt Pathway. Chem. Biol. Drug Des. 2024, 103, e14450. [Google Scholar] [CrossRef]
  137. Zhang, R.; Zhang, Q.; Deng, F.; Liu, L. Potential Applications of Pfkfb in Cancer Treatment Strategies. Int. J. Biol. Macromol. 2025, 320, 145860. [Google Scholar] [CrossRef] [PubMed]
  138. Li, L.B.; Yang, L.X.; Liu, L.; Liu, F.R.; Li, A.H.; Zhu, Y.L.; Wen, H.; Xue, X.; Tian, Z.X.; Sun, H.; et al. Targeted Inhibition of the Hnf1a/Shh Axis by Triptolide Overcomes Paclitaxel Resistance in Non-Small Cell Lung Cancer. Acta Pharmacol. Sin. 2024, 45, 1060–1076. [Google Scholar] [CrossRef] [PubMed]
  139. Xie, Y.; Ding, J.; Gao, J.; Zhang, J.; Cen, S.; Zhou, J. Triptolide Reduces Pd-L1 through the Egfr and Ifn-Gamma/Irf1 Dual Signaling Pathways. Int. Immunopharmacol. 2023, 118, 109993. [Google Scholar] [CrossRef] [PubMed]
  140. Shi, J.; Wang, Y.; Wu, Y.; Li, J.; Fu, C.; Li, Y.; Xie, X.; Fan, X.; Hu, Y.; Hu, C.; et al. Tumor Microenvironment Ros/Ph Cascade-Responsive Supramolecular Nanoplatform with Ros Regeneration Property for Enhanced Hepatocellular Carcinoma Therapy. ACS Appl. Mater. Interfaces 2024, 16, 7576–7592. [Google Scholar] [CrossRef]
  141. Liu, W.; Sun, C.; Dai, Y.; Wang, H.; Ashrafizadeh, M.; Conde, J.; Yang, L.; He, W. A Tumor Microenvironment-Responsive Zr-Mof Nanosystem for Co-Delivering Sihif-1alpha and Triptolide Enhances Photodynamic Therapy in Esophageal Cancer by Amplifying Ros Generation and Reversing Hypoxia. Mater. Today Bio 2025, 34, 102183. [Google Scholar] [CrossRef]
  142. Wang, S.; Jiang, H.; Wang, J.; Wu, H.; Wu, T.; Ni, M.; Zhao, Q.; Ji, Y.; Zhang, Z.; Tang, C.; et al. Superior in Vitro Anticancer Effect of Biomimetic Paclitaxel and Triptolide Co-Delivery System in Gastric Cancer. J. Biomed. Res. 2021, 35, 327–338. [Google Scholar] [CrossRef]
  143. Fang, K.; Sun, Y.; Yang, J.; Hu, X.; Chen, M.; Li, R.; Yang, X.; Fan, T.; Wu, J.; Tong, X.; et al. A Dual Stimuli-Responsive Nanoplatform Loaded Pt(Iv) -Triptolide Prodrug for Achieving Synergistic Therapy toward Breast Cancer. Adv. Healthc. Mater. 2023, 12, e2301328. [Google Scholar] [CrossRef]
  144. Chen, P.; Zhong, X.; Song, Y.; Zhong, W.; Wang, S.; Wang, J.; Huang, P.; Niu, Y.; Yang, W.; Ding, Z.; et al. Triptolide Induces Apoptosis and Cytoprotective Autophagy by Ros Accumulation Via Directly Targeting Peroxiredoxin 2 in Gastric Cancer Cells. Cancer Lett. 2024, 587, 216622. [Google Scholar] [CrossRef] [PubMed]
  145. Kuo, C.S.; Yang, C.Y.; Lin, C.K.; Lin, G.J.; Sytwu, H.K.; Chen, Y.W. Triptolide Suppresses Oral Cancer Cell Pd-L1 Expression in the Interferon-Gamma-Modulated Microenvironment in Vitro, in Vivo, and in Clinical Patients. Biomed. Pharmacother. 2021, 133, 111057. [Google Scholar] [CrossRef] [PubMed]
  146. Xiao, Y.; Yin, J.; Liu, P.; Zhang, X.; Lin, Y.; Guo, J. Triptolide-Induced Cuproptosis Is a Novel Antitumor Strategy for the Treatment of Cervical Cancer. Cell Mol. Biol. Lett. 2024, 29, 113. [Google Scholar] [CrossRef] [PubMed]
  147. Lim, S.H.; Saluja, A.; Vickers, S.; Hong, J.Y.; Kim, S.T.; Lavania, S.; Pandey, S.; Gupta, V.K.; Velagapudi, M.R.; Lee, J. The Safety and Efficacy Outcomes of Minnelide Given Alone or in Combination with Paclitaxel in Advanced Gastric Cancer: A Phase I Trial. Cancer Lett. 2024, 597, 217041. [Google Scholar] [CrossRef]
  148. Borazanci, E.; Saluja, A.; Gockerman, J.; Velagapudi, M.; Korn, R.; Von Hoff, D.; Greeno, E. First-in-Human Phase I Study of Minnelide in Patients with Advanced Gastrointestinal Cancers: Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity. Oncologist 2024, 29, 132–141. [Google Scholar] [CrossRef]
  149. Skorupan, N.; Ahmad, M.I.; Steinberg, S.M.; Trepel, J.B.; Cridebring, D.; Han, H.; Von Hoff, D.D.; Alewine, C. A Phase II Trial of the Super-Enhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas. Future Oncol. 2022, 18, 2475–2481. [Google Scholar] [CrossRef]
  150. Song, J.; He, G.N.; Dai, L. A Comprehensive Review on Celastrol, Triptolide and Triptonide: Insights on Their Pharmacological Activity, Toxicity, Combination Therapy, New Dosage Form and Novel Drug Delivery Routes. Biomed. Pharmacother. 2023, 162, 114705. [Google Scholar] [CrossRef]
  151. Bao, S.; Yi, M.; Xiang, B.; Chen, P. Antitumor Mechanisms and Future Clinical Applications of the Natural Product Triptolide. Cancer Cell Int. 2024, 24, 150. [Google Scholar] [CrossRef] [PubMed]
  152. Wang, N.; Min, X.; Ma, N.; Zhu, Z.; Cao, B.; Wang, Y.; Yong, Q.; Huang, J.; Li, K. The Negative Impact of Triptolide on the Immune Function of Human Natural Killer Cells. Pharmaceuticals 2023, 16, 458. [Google Scholar] [CrossRef] [PubMed]
  153. Sun, W.; Sanderson, P.E.; Zheng, W. Drug Combination Therapy Increases Successful Drug Repositioning. Drug Discov. Today 2016, 21, 1189–1195. [Google Scholar] [CrossRef] [PubMed]
Cancers 18 01196 g001
Figure 1. Chemical structure of TPL. (Adopted from FDA website https://precision.fda.gov/home, accessed on 19 January 2026).
Figure 1. Chemical structure of TPL. (Adopted from FDA website https://precision.fda.gov/home, accessed on 19 January 2026).
Cancers 18 01196 g001
Cancers 18 01196 g002
Figure 2. Reported systemic toxicities associated with TPL (created with BioRender.com).
Figure 2. Reported systemic toxicities associated with TPL (created with BioRender.com).
Cancers 18 01196 g002
Cancers 18 01196 g003
Figure 3. Mechanism of TPL inducing cell death. First, TPL covalently binds to the XPB subunit and inhibits its ATPase activity, thereby impairing the function of the TFIIH complex; Second, TPL promotes the phosphorylation and ubiquitination of RPB1, leading to its depletion. Together, these mechanisms inhibit the activity of key transcription factors, resulting in suppressed cell proliferation and induction of apoptosis (created with BioRender.com).
Figure 3. Mechanism of TPL inducing cell death. First, TPL covalently binds to the XPB subunit and inhibits its ATPase activity, thereby impairing the function of the TFIIH complex; Second, TPL promotes the phosphorylation and ubiquitination of RPB1, leading to its depletion. Together, these mechanisms inhibit the activity of key transcription factors, resulting in suppressed cell proliferation and induction of apoptosis (created with BioRender.com).
Cancers 18 01196 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Geng, Y.; Kritzer, B.; Nazarian, J. Triptolide: A Narrative Review of Its Traditional Use, Derivatives, Pharmacology, Antitumor Effect, and Clinical Applications. Cancers 2026, 18, 1196. https://doi.org/10.3390/cancers18081196

AMA Style

Geng Y, Kritzer B, Nazarian J. Triptolide: A Narrative Review of Its Traditional Use, Derivatives, Pharmacology, Antitumor Effect, and Clinical Applications. Cancers. 2026; 18(8):1196. https://doi.org/10.3390/cancers18081196

Chicago/Turabian Style

Geng, Yibo, Bettina Kritzer, and Javad Nazarian. 2026. "Triptolide: A Narrative Review of Its Traditional Use, Derivatives, Pharmacology, Antitumor Effect, and Clinical Applications" Cancers 18, no. 8: 1196. https://doi.org/10.3390/cancers18081196

APA Style

Geng, Y., Kritzer, B., & Nazarian, J. (2026). Triptolide: A Narrative Review of Its Traditional Use, Derivatives, Pharmacology, Antitumor Effect, and Clinical Applications. Cancers, 18(8), 1196. https://doi.org/10.3390/cancers18081196

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop